

8-30-07 DRAFT

Science Advisory Board (SAB) Ethylene Oxide Review Panel Draft Advisory Report

-- Do Not Cite or Quote --

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON D.C. 20460

OFFICE OF THE ADMINISTRATOR
SCIENCE ADVISORY BOARD

DATE

Honorable Stephen L. Johnson
Administrator
U.S. Environmental Protection Agency
1200 Pennsylvania Avenue, N.W.
Washington, DC 20460

Subject: Review of Office of Research and Development (ORD) draft assessment entitled, "Evaluation of the Carcinogenicity of Ethylene Oxide".

Dear Administrator Johnson:

In response to a request from EPA's Office of Research and Development (ORD), the Science Advisory Board (SAB) convened an expert panel to conduct a peer review of EPA's draft assessment entitled, "Evaluation of the Carcinogenicity of Ethylene Oxide". EPA last published an assessment of the potential carcinogenicity of EtO in 1985. The current assessment evaluates the more recent database on the carcinogenicity of EtO and focuses on lifetime cancer risk from inhalation exposure.

The SAB was asked to comment on three issues, including carcinogenic hazard, derivation of a cancer unit risk value for inhalation exposure to EtO, and uncertainties associated with the carcinogenicity assessment. The report contains a number of recommendations that are aimed at making the assessment more transparent and improve the scientific bases for the conclusions presented. The Panel's key recommendations are highlighted below.

A majority of the Panel agreed with the conclusion in the draft document that the available evidence supports a descriptor of "Carcinogenic to Humans" although some Panel members concluded that the descriptor "Likely to be Carcinogenic to Humans" was more appropriate. There was consensus that the epidemiological data regarding ethylene oxide carcinogenicity were not in and of themselves sufficient to prove a causal association between human exposure and cancer. Differing views as to the appropriate carcinogenicity descriptor for ethylene oxide were based on differences of opinion as to whether criteria necessary for designation as "Carcinogenic to Humans" in the absence of conclusive evidence from epidemiologic studies were met. The majority of Panel members thought that the combined weight of the epidemiological, experimental animal, and mutagenicity evidence was sufficient to conclude that EtO is carcinogenic to humans.

The Panel concluded that the assessment would be improved by: 1) a better introduction to the hazard characterization section, including a brief description of the information that will be presented; 2) a clear articulation of the criteria by which epidemiologic studies were judged as to strengths and weaknesses; 3) addition of a more inclusive summary figure and/or table at the beginning of section 3.0; and 4) inclusion and expansion of material now provided in Appendix A within the main body of the draft assessment.

The Panel concurred that the NIOSH cohort is the best single epidemiological data set with which to study the relationship of cancer mortality to the full range of occupational exposures to EtO. That said, the Panel encouraged the EPA to broadly consider all of the epidemiological data in developing its final Assessment.

The Panel identified several important shortcomings in the linear regression modeling approach used to establish the point of departure for low dose extrapolation of cancer risk due to EtO. The Panel was unanimous in its recommendation that the EPA develop its risk models based on direct analysis of the individual exposure and cancer outcome data for the NIOSH cohort rather than the approach based on grouped data that is presently used.

The Panel discussed whether low dose extrapolation of risk to environmental EtO exposure levels should be linear (following Cancer Guideline defaults for carcinogenic agents operating via a mutagenic MOA) or whether plausible biological mechanisms argued for a non-linear form for the low dose response relationship. With appropriate discussion of the statistical and biological uncertainties, several Panel members strongly advocated that both linear and nonlinear calculations be presented in the final EtO Risk Assessment.

The Draft Assessment appropriately characterizes the magnitude of the risk associated with EtO as “weak”. This finding is well substantiated by the epidemiologic evidence where a relatively small number of excess cancers are found above background even among highly exposed individuals. However, the magnitude of risk suggested by the unit risk estimate is somewhat at odds with this concept. In our report, we provide specific recommendations for addressing this apparent inconsistency.

In accordance with EPA guidance, the draft assessment applied an Age Dependent Adjustment Factor (ADAF) to adjust the unit risk for early life exposure. While the Panel felt that the application of a default value by the Agency was appropriate, the description in the Draft Assessment was not adequate, particularly for those not familiar with the EPA Guidance.

The Panel appreciates both the public health and economic significance of EPA’s EtO risk assessment. A more thorough discussion of the Panel’s recommendations is included in the body of the report. Some of the Panel’s recommendations, such as the reanalysis of the NIOSH cohort using data from individuals, will require significant effort. The Panel encourages the Agency to devote sufficient resources to make implementation of these recommendations possible. We look forward to receiving the Agency’s response and appreciate the opportunity to provide EPA with advice on this important subject.

8-30-07 DRAFT

Science Advisory Board (SAB) Ethylene Oxide Review Panel Draft Advisory Report

-- Do Not Cite or Quote --

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

Sincerely,

Dr. Stephen Roberts, Chair
SAB Ethylene Oxide Review Panel

Dr. Granger Morgan, Chair
EPA Science Advisory Board

8-30-07 DRAFT

Science Advisory Board (SAB) Ethylene Oxide Review Panel Draft Advisory Report

-- Do Not Cite or Quote --

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

NOTICE

This report has been written as part of the activities of the EPA Science Advisory Board, a public advisory committee providing extramural scientific information and advice to the Administrator and other officials of the Environmental Protection Agency. The Board is structured to provide balanced, expert assessment of scientific matters related to problems facing the Agency. This report has not been reviewed for approval by the Agency and, hence, the contents of this report do not necessarily represent the views and policies of the Environmental Protection Agency, nor of other agencies in the Executive Branch of the Federal government, nor does mention of trade names or commercial products constitute a recommendation for use. Reports of the EPA Science Advisory Board are posted on the EPA Web site at: <http://www.epa.gov/sab>.

8-30-07 DRAFT

Science Advisory Board (SAB) Ethylene Oxide Review Panel Draft Advisory Report

-- Do Not Cite or Quote --

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

U.S. Environmental Protection Agency

Science Advisory Board

Ethylene Oxide Review Panel*

CHAIR

Dr. Stephen M. Roberts, Professor, Department of Physiological Sciences, Director, Center for Environmental and Human Toxicology, University of Florida,

OTHER SAB MEMBERS

Dr. Timothy Buckley, Associate Professor and Chair, Division of Environmental Health Sciences, School of Public Health, The Ohio State University

Dr. Montserrat Fuentes, Associate Professor, Department of Statistics, North Carolina State University,

Dr. Dale Hattis, Research Professor, Center for Technology, Environment, and Development, George Perkins Marsh Institute, Clark University

Dr. James Kehrer, Dean, College of Pharmacy, Washington State University

Dr. James E. Klaunig, Robert B. Forney Professor of Toxicology, Department of Pharmacology and Toxicology, School of Medicine, Indiana University

Dr. Mark Miller, Public Health Medical Officer, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency

Dr. Maria Morandi, Assistant Professor of Environmental Science & Occupational Health, Department of Environmental Sciences, School of Public Health, University of Texas - Houston Health Science Center

Dr. Robert Schnatter, Senior Scientific Advisor, Occupational and Public Health, ExxonMobil Biomedical Sciences, Inc.

Dr. Anne Sweeney, Associate Professor, Department of Epidemiology and Biostatistics, School of Rural Public Health, TAMU System Health Science Center

CONSULTANTS

Dr. Steven Alan Belinsky, Co-Director, Cancer Epidemiology and Control Program for the University of New Mexico

8-30-07 DRAFT

Science Advisory Board (SAB) Ethylene Oxide Review Panel Draft Advisory Report

-- Do Not Cite or Quote --

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

Dr. Norman Drinkwater, Professor and Chair of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin Medical School

Dr. Steven Heeringa, Director, Division of Surveys and Technologies, Institute for Social Research, University of Michigan

Dr. Ulrike Luderer, Associate Professor, Department of Medicine, Division of Occupational and Environmental Medicine, University of California at Irvine

Dr. James Swenberg, Kenan Distinguished Professor of Environmental Sciences and Engineering, Nutrition and Pathology and Laboratory Medicine, Schools of Public Health and Medicine, University of North Carolina at Chapel Hill.

Dr. Vernon Walker, Clinical Associate Professor; Research Scientist, Molecular Biology and Lung Cancer Program, College of Pharmacy, Lovelace Respiratory Research Institute

SCIENCE ADVISORY BOARD STAFF

Dr. Suhair Shallal, Designated Federal Officer, 1200 Pennsylvania Avenue, Washington, DC, 20450, Phone: 202-343-9977, Fax: 202-233-0643, (shallal.suhair@epa.gov)

TABLE OF CONTENTS

EXECUTIVE SUMMARY 8

ISSUE 1: CARCINOGENIC HAZARD (SECTION 3 AND APPENDIX A OF THE EPA DRAFT ASSESSMENT)..... 8

ISSUE 2: RISK ESTIMATION (SECTION 4 AND APPENDICES C AND D OF THE EPA DRAFT ASSESSMENT) .. 10

INTRODUCTION 14

CHARGE QUESTIONS 14

Issue 1: Carcinogenic Hazard (Section 3 and Appendix A of the Draft Assessment)..... 14

Issue 2: Risk Estimation (Section 4 and Appendices C and D of the Draft Assessment)..... 15

Issue 3: Uncertainty (Sections 3 and 4) 16

RESPONSES TO THE CHARGE QUESTIONS 17

CHARGE QUESTION 1- HAZARD DESCRIPTOR 17

1.a. Qualitative Characterization of Epidemiology Data..... 17

1.b. Relevant Additional Key Studies..... 19

1.c. Mode of Action 24

1.d. Hazard Characterization..... 25

CHARGE QUESTION 2- DOSE-RESPONSE ANALYSIS 27

2.a. Selection of Epidemiology Studies 28

2.b. Methods of Analysis 31

2.c. Age-dependent Adjustment 41

2.d. Low-dose Extrapolation 41

2.e. Extrapolation from animal studies 42

REFERENCES 43

APPENDIX A..... 46

APPENDIX B..... 66

APPENDIX C..... 74

APPENDIX D..... 85

ATTACHMENT 1 MEMO AND CHARGE QUESTIONS 90

EXECUTIVE SUMMARY

EPA's Office of Research and Development (ORD) requested that the Science Advisory Board (SAB) review its draft assessment entitled, "Evaluation of the Carcinogenicity of Ethylene Oxide." EPA last published a health assessment of the potential carcinogenicity of Ethylene Oxide (EtO) in 1985 (U.S. EPA, 1985). EPA's ORD completed a review of the more recent database on the carcinogenicity of EtO, pertinent data from the 1985 assessment, and several reviews and assessments issued by other organizations. The Agency's Draft Assessment focuses on lifetime cancer risk from inhalation exposure. The EtO Review Panel of the EPA Science Advisory Board met in January 2007 to deliberate on charge questions raised by ORD. These questions focused on three issues, including carcinogenic hazard, derivation of a cancer unit risk value for inhalation exposure to EtO, and uncertainties associated with the analysis.

This Executive Summary highlights the outcome of the Panel's deliberations. It includes the context for the charge questions and issues raised for consideration by EPA, and the conclusions reached by the SAB Review Panel. While the Agency requested that the Panel respond to three separate multi-part charge questions, the Panel has presented their response to the third charge question in the context of each of the other two charge questions. Therefore, this report is structured so that the comments concerning Uncertainty (Issue 3) are integrated in the responses to the Carcinogenic Hazard (Issue 1) and Risk Estimation (Issue 2) sections.

Issue 1: Carcinogenic Hazard (Section 3 and Appendix A of the EPA Draft Assessment)

1. Do the available data and discussion in the draft document support the hazard conclusion that EtO is carcinogenic to humans based on the weight-of-evidence descriptors in EPA's 2005 Guidelines for Carcinogen Risk Assessment? In your response, please include consideration of the following:

1. a. EPA concluded that the epidemiological evidence on EtO carcinogenicity was strong, but less than completely conclusive. Does the draft document provide sufficient description of the studies, balanced treatment of positive and negative results, and a rigorous and transparent analysis of the data used to assess the carcinogenic hazard of ethylene oxide (EtO) to humans? Please comment on the EPA's characterization of the body of epidemiological data reviewed. Considerations include: a) the consistency of the findings, including the significance of differences in results using different exposure metrics, b) the utility of the internal (based on exposure category) versus external (e.g., SMR and SIR) comparisons of cancer rates, c) the magnitude of the risks, and d) the strength of the epidemiological evidence.

A majority of the Panel agreed with the conclusion in the draft document that the available evidence supports a descriptor of "Carcinogenic to Humans" although some Panel members concluded that the descriptor "Likely to be Carcinogenic to Humans" was

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 more appropriate. There was consensus that the epidemiological data regarding ethylene
2 oxide carcinogenicity were not in and of themselves sufficient to prove a causal
3 association between human exposure and cancer. Differing views as to the appropriate
4 descriptor for ethylene oxide were based on differences of opinion as to whether criteria
5 necessary for designation as “Carcinogenic to Humans” in the absence of conclusive
6 evidence from epidemiologic studies were met. The majority of Panel members thought
7 that the combined weight of the epidemiological, experimental animal, and mutagenicity
8 evidence was sufficient to conclude that EtO is carcinogenic to humans.
9

10 The Panel concluded that the assessment would be improved by: 1) a better introduction
11 to the hazard characterization section, including a brief description of the information
12 that will be presented; 2) a clear articulation of the criteria by which epidemiologic
13 studies were judged as to strengths and weaknesses; 3) addition of a more inclusive
14 summary figure and/or table at the beginning of section 3.0; and 4) inclusion of material
15 now provided in Appendix A within the main body of the draft assessment.
16

17 The Panel agreed with the EPA in their reliance on “internal” estimates of cancer rates
18 rather than “external” comparisons (SMR, SIR) due to well recognized limitations to the
19 latter method of analysis.
20

21 The Draft Assessment appropriately characterizes the magnitude of the risk associated
22 with EtO as “weak”. This finding is substantiated by the epidemiologic evidence where a
23 relatively small number of excess cancers are found above background even among
24 highly exposed individuals. However, the magnitude of risk suggested by the unit risk
25 estimate is somewhat at odds with this concept. Subsequent recommendations in our
26 report may address this apparent inconsistency.
27

28 ***1. b. Are there additional key published studies or publicly available scientific reports that***
29 ***are missing from the draft document and that might be useful for the discussion of the***
30 ***carcinogenic hazard of EtO?***
31

32 The Panel agreed that the discussion of endogenous metabolic production of ethylene
33 oxide and the formation of background adducts should be expanded.
34

35 The Panel believed that the description of studies of DNA adduct formation resulting
36 from EtO exposure appears incomplete and superficial. This discussion should be
37 expanded – both in terms of the number of studies cited and the depth of the discussion.
38

39 Since ethylene is metabolized to EtO, some members recommended the inclusion of the
40 ethylene body of literature for consideration. Most members were hesitant about adding
41 them to the document, but if added, they cautioned that a discussion of the caveats
42 associated with their interpretation relative to ethylene oxide should be included.
43

44 ***1. c. Do the available data and discussion in the draft document support the mode of***
45 ***action conclusions?***

1
2 The Panel agreed with the Draft Assessment conclusion of a mutagenic mode of action.
3 However, an expanded discussion of the formation of DNA adducts and mutagenicity is
4 warranted.
5

6 ***1.d. Does the hazard characterization discussion for EtO provide a scientifically-balanced***
7 ***and sound description that synthesizes the human, laboratory animal, and supporting***
8 ***(e.g., in vitro) evidence for human carcinogenic hazard?***
9

10 While some members of the Panel found the hazard characterization section of the Draft
11 Assessment to be satisfactory, a majority expressed concerns that this section did not
12 achieve the necessary level of rigor and balance. An issue in this characterization,
13 particularly in the face of epidemiological data that are not strongly conclusive, is
14 whether the presumed precursor events leading to cancer in animals, such as mutations
15 and/or chromosomal aberrations, are observed in humans. This issue needs to be
16 addressed in greater detail.
17

18 **Issue 2: Risk Estimation (Section 4 and Appendices C and D of the EPA Draft**
19 **Assessment)**
20

21 ***2. Do the available data and discussion in the draft document support the approaches***
22 ***taken by EPA in its derivation of cancer risk estimates for EtO? In your response, please***
23 ***include consideration of the following:***
24

25 ***2.a. EPA concluded that the epidemiological evidence alone was strong but less than***
26 ***completely conclusive (although EPA characterized the total evidence - from human,***
27 ***laboratory animal, and in vitro studies - as supporting a conclusion that EtO as***
28 ***"carcinogenic to humans"). Is the use of epidemiological data, in particular the***
29 ***Steenland et al. (2003, 2004) data set, the most appropriate for estimating the magnitude of***
30 ***the carcinogenic risk to humans from environmental EtO exposures? Are the scientific***
31 ***justifications for using this data set transparently described? Is the basis for selecting the***
32 ***Steenland et al. data over other available data (e.g., the Union Carbide data) for***
33 ***quantifying risk adequately described?***
34

35 The Panel concurred that the NIOSH cohort is the best single epidemiological data set
36 with which to study the relationship of cancer mortality to the full range of occupational
37 exposures to EtO. That said, the Panel encouraged the EPA to broadly consider all of the
38 epidemiological data in developing its final Assessment. In particular, the Panel
39 encourages the EPA to explore uses for the Greenberg et al. (1990) data on cancer
40 outcomes and EtO exposures for 2174 Union Carbide workers from its two Kana Valley,
41 West Virginia facilities. (See also Teta et al. 1993; Teta et al., 1999).
42

43 The Panel encouraged the EPA to investigate potential instability that may result from
44 interaction between the chosen time metric for the dose response model and the treatment

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 of time in the estimated exposure (i.e., log cumulative exposure with 15 year lag) that is
2 the independent variable in that dose-response model.
3

4 ***2.b. Assuming that Steenland et al. (2003, 2004) is the most appropriate data set, is the use***
5 ***of a linear regression model fit to Steenland et al.'s categorical results for all***
6 ***lymphohematopoietic cancer in males in only the lower exposure groups scientifically and***
7 ***statistically appropriate for estimating potential human risk at the lower end of the***
8 ***observable range? Is the use of the grouping of all lymphohematopoietic cancer for the***
9 ***purpose of estimating risk appropriate? Are there other appropriate analytical approaches***
10 ***that should be considered for estimating potential risk in the lower end of the observable***
11 ***range? Is EPA's choice of a preferred model adequately supported and justified? In***
12 ***particular, has EPA adequately explained its reasons for not using a quadratic model***
13 ***approach such as that of Kirman et al. (2004) based? What recommendations would you***
14 ***make regarding low-dose extrapolation below the observed range?***
15

16 The Panel identified several important shortcomings in the linear regression modeling
17 approach used to establish the point of departure for low dose extrapolation of cancer risk
18 due to EtO. The Panel was unanimous in its recommendation that the EPA develop its
19 risk models based on direct analysis of the individual exposure and cancer outcome data
20 for the NIOSH cohort rather than the approach based on published grouped data that is
21 presently used. The suggested analysis will require EPA to acquire or otherwise access
22 individual data and develop appropriate methods of analysis. The panel recommends that
23 the Agency allocate the appropriate resources to conduct this analysis.
24

25 The Panel discussed whether low dose extrapolation of risk due to environmental EtO
26 exposure levels should be linear (following Cancer Guideline defaults for carcinogenic
27 agents operating via a mutagenic MOA) or whether plausible biological mechanisms
28 argued for a non-linear form for the low dose response relationship. With appropriate
29 discussion of the statistical and biological uncertainties, Panel members strongly
30 advocated that both linear and nonlinear calculations be presented in the final EtO Risk
31 Assessment.
32

33 In conjunction with its recommendation to use the individual NIOSH cohort data to
34 model the relationship of cancer risk to exposures in the occupational range, the Panel
35 recommended that the Agency explore the use of the full NIOSH data set to estimate the
36 cancer slope coefficients that will in turn be used to extrapolate risk below the established
37 point of departure. The use of different data to estimate different dose response curves
38 should be avoided unless there is both strong biologic and statistical justification for
39 doing so. The Panel believed this justification was not made in the Agency's draft
40 assessment.
41

42 Although the analysis based on total lymphohematopoietic (LH) cancers might have
43 value as part of a complete risk assessment, the rationale for this aggregate grouping
44 needs to be better justified. The Panel recommends that data be analyzed by subtype of

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 LH cancers (e.g. lymphoid, myeloid) and strong consideration be given to these more
2 biologically justified groupings as primary disease endpoints.

3
4 The Panel was divided in its views concerning the appropriateness of estimating the
5 population unit risk for LH cancer based only on the NIOSH data for males. Several
6 Panel members pointed out that a standard approach in cancer epidemiology and risk
7 analysis begins by conducting separate dose-response analyses on males and females and
8 combining the data only if the results are similar. Conducting separate analyses for
9 males and females is also the standard practice when analyzing data from animal
10 carcinogenicity bioassays. A second approach to dealing with the possibility of gender
11 differences in response is to include gender as a fixed effect in the statistical modeling of
12 the data and determine whether gender or its interaction with other predictors (e.g.,
13 gender x exposure) are significant explanatory variables. If so, the combined model with
14 the estimated gender effects could be used directly or separate, gender-specific dose-
15 response analysis would be performed. If not, the gender effects could be dropped and
16 the model re-estimated for the combined male and female data. In addition, the Agency
17 should test whether the male/female differences are mitigated by use of alternate disease
18 endpoints discussed in the previous paragraph.

19
20 ***2.c. Is the incorporation of age-dependent adjustment factors in the lifetime cancer unit***
21 ***risk estimate, in accordance with EPA's Supplemental Guidance (U.S. 2005b), appropriate***
22 ***and transparently described?***

23
24 In accordance with EPA guidance, the Draft Assessment applied an Age Dependent
25 Adjustment Factor (ADAF) to adjust the unit risk for early life exposure. While the
26 majority of the Panel felt that the application of a default value by the Agency was
27 appropriate due to lack of data, the description in the Draft Assessment was not adequate,
28 particularly for those not familiar with the EPA's Supplemental Guidance.

29
30 ***2.d Is the use of different models for estimation of potential carcinogenic risk to humans***
31 ***from the higher exposure levels more typical of occupational exposures (versus the lower***
32 ***exposure levels typical of environmental exposures) appropriate and transparently***
33 ***described in Section 4.5?***

34
35 While the method was transparently described, most of the Panel did not agree with the
36 estimation based on two different models for two different parts of the dose response
37 curve (see response to 2b). The use of different data to estimate different dose response
38 models curves should be avoided unless there is both strong biological and statistical
39 justification for doing so. The Panel believed this justification was not made in the
40 Agency's draft report.

41
42 ***2.e. Are the methodologies used to estimate the carcinogenic risk based on rodent data***
43 ***appropriate and transparently described? Is the use of "ppm equivalence" adequate for***
44 ***interspecies scaling of EtO exposures from the rodent data to humans?***

8-30-07 DRAFT

Science Advisory Board (SAB) Ethylene Oxide Review Panel Draft Advisory Report

-- Do Not Cite or Quote --

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 The ppm equivalence method is a reasonable approach for interspecies scaling of EtO
2 exposures from rodent data to humans. If the use of animal data becomes more important
3 (i.e., the principal basis for the ethylene oxide unit risk value), more sophisticated
4 approaches such as PBPK modeling should be considered.
5

1

2

INTRODUCTION

3 This report was prepared by the Science Advisory Board (SAB) Ethylene Oxide (EtO)
4 Review Panel (the "Panel") in response to a request by EPA's Office of Research and
5 Development (ORD) to review their draft Evaluation of the Carcinogenicity of Ethylene
6 Oxide. According to the document, EPA last published an assessment of the potential
7 carcinogenicity of EtO in 1985. The current assessment reviews the more recent database on
8 the carcinogenicity of EtO.

9 EtO is a gas at room temperature. It is manufactured from ethylene and used primarily as a
10 chemical intermediate in the manufacture of ethylene glycol. It is also used as a sterilizing
11 agent for medical equipment and as a fumigating agent for spices. The largest sources of
12 human exposure are in occupations involving contact with the gas in plants (facilities) and in
13 hospitals that sterilize medical equipment. EtO can also be inhaled by residents living near
14 production or sterilizing/fumigating facilities. The Draft Assessment describes the derivation
15 of inhalation unit risk estimates for cancer mortality and incidence based on human
16 epidemiological data.

17 ORD identified 3 issues where they were seeking the SAB's advice and recommendations.
18 These included the proposed carcinogenic hazard, risk calculations and uncertainty. The
19 SAB EtO Review Panel was asked to comment on the scientific soundness of this risk
20 assessment.

21 The Panel deliberated on the charge questions during their January 18-19, 2007 face-to-face
22 meeting and during a conference call on May 29, 2007. The responses that follow represent
23 the views of the Panel. In all cases, there was agreement by a majority of the Panel members
24 as to a particular recommendation. In some cases, there were some Panel members that had
25 a differing point of view; these instances have been noted throughout the report. The specific
26 charge questions to the Panel are as follows:

27

Charge Questions

28

29 The memo requesting this review along with the complete charge to the Panel can be found
30 in its entirety in Attachment 1. Below is an abbreviated version of the charge questions.

31

Issue 1: Carcinogenic Hazard (Section 3 and Appendix A of the Draft)

32

33 1. Do the available data and discussion in the draft document support the hazard conclusion
34 that EtO is carcinogenic to humans based on the weight-of-evidence descriptors in EPA's
35 2005 *Guidelines for Carcinogen Risk Assessment*? In your response, please include
36 consideration of the following:

37

38 1.a EPA concluded that the epidemiological evidence on EtO carcinogenicity was strong, but
39 less than completely conclusive. Does the draft document provide sufficient description of
40
41

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 the studies, balanced treatment of positive and negative results, and a rigorous and
2 transparent analysis of the data used to assess the carcinogenic hazard of ethylene oxide
3 (EtO) to humans? Please comment on the EPA's characterization of the body of
4 epidemiological data reviewed. Considerations include: a) the consistency of the findings,
5 including the significance of differences in results using different exposure metrics, b) the
6 utility of the internal (based on exposure category) versus external (e.g., SMR and SIR)
7 comparisons of cancer rates, c) the magnitude of the risks, and d) the strength of the
8 epidemiological evidence.

9
10 1.b. Are there additional key published studies or publicly available scientific reports that are
11 missing from the draft document and that might be useful for the discussion of the
12 carcinogenic hazard of EtO?

13
14 1.c. Do the available data and discussion in the draft document support the mode of action
15 conclusions?

16
17 1.d. Does the hazard characterization discussion for EtO provide a scientifically-balanced
18 and sound description that synthesizes the human, laboratory animal, and supporting (e.g., *in*
19 *vitro*) evidence for human carcinogenic hazard?

20
21 **Issue 2: Risk Estimation (Section 4 and Appendices C and D)**

22
23 2. Do the available data and discussion in the draft document support the approaches taken
24 by EPA in its derivation of cancer risk estimates for EtO? In your response, please include
25 consideration of the following:

26
27 2.a. EPA concluded that the epidemiological evidence alone was strong but less than
28 completely conclusive (although EPA characterized the total evidence - from human,
29 laboratory animal, and *in vitro* studies - as supporting a conclusion that EtO as "carcinogenic
30 to humans"). Is the use of epidemiological data, in particular the Steenland et al. (2003,
31 2004) data set, the most appropriate for estimating the magnitude of the carcinogenic risk to
32 humans from environmental EtO exposures? Are the scientific justifications for using this
33 data set transparently described? Is the basis for selecting the Steenland et al. data over other
34 available data (e.g., the Union Carbide data) for quantifying risk adequately described?

35
36 2.b. Assuming that Steenland et al. (2003, 2004) is the most appropriate data set, is the use of
37 a linear regression model fit to Steenland et al.'s categorical results for all
38 lymphohematopoietic cancer in males in only the lower exposure groups scientifically and
39 statistically appropriate for estimating potential human risk at the lower end of the
40 observable range? Is the use of the grouping of all lymphohematopoietic cancer for the
41 purpose of estimating risk appropriate? Are there other appropriate analytical approaches that
42 should be considered for estimating potential risk in the lower end of the observable range?
43 Is EPA's choice of a preferred model adequately supported and justified? In particular, has
44 EPA adequately explained its reasons for not using a quadratic model approach such as that

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 of Kirman et al. (2004) based? What recommendations would you make regarding low-dose
2 extrapolation below the observed range?

3
4 2.c. Is the incorporation of age-dependent adjustment factors in the lifetime cancer unit risk
5 estimate, in accordance with EPA's Supplemental Guidance (U.S. 2005b), appropriate and
6 transparently described?

7
8 2.d Is the use of different models for estimation of potential carcinogenic risk to humans
9 from the higher exposure levels more typical of occupational exposures (versus the lower
10 exposure levels typical of environmental exposures) appropriate and transparently described
11 in Section 4.5?

12
13 2.e. Are the methodologies used to estimate the carcinogenic risk based on rodent data
14 appropriate and transparently described? Is the use of "ppm equivalence" adequate for
15 interspecies scaling of EtO exposures from the rodent data to humans?

16
17 **Issue 3: Uncertainty (Sections 3 and 4)**

18
19 1. EPA's *Risk Characterization Handbook* requires that assessments address in a transparent
20 manner a number of important factors. Please comment on how well this assessment clearly
21 describes, characterizes and communicates the following:

- 22 a. The assessment approach employed;
23 b. The use of assumptions and their impact on the assessment;
24 c. The use of extrapolations and their impact on the assessment;
25 d. Plausible alternatives and the choices made among those alternatives;
26 e. The impact of one choice versus another on the assessment;
27 f. Significant data gaps and their implications for the assessment;
28 g. The scientific conclusions identified separately from default assumptions and policy calls;
29 h. The major risk conclusions and the assessor's confidence and uncertainties in them, and;
30 i. The relative strength of each risk assessment component and its impact on the overall
31 assessment.

32
33

RESPONSES TO THE CHARGE QUESTIONS

Specific responses to each of the charge questions are presented below. The Panel has responded to Charge Questions 1 and 2 and has tried to incorporate their comments regarding Charge Question 3 within those responses. A separate response for Charge Question 3 was not deemed necessary since issues of uncertainty were addressed in the responses to charge questions 1 and 2.

Charge Question 1- Hazard Descriptor

The Agency's assessment concludes that in accordance with EPA's 2005 *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005a), EtO was characterized as carcinogenic to humans based on the total weight of evidence. This evidence, as assessed by EPA, included: a) strong, though less than completely conclusive, evidence of carcinogenicity from human studies; b) sufficient evidence of carcinogenicity in laboratory animals; c) EtO is a direct-acting alkylating agent with clear evidence of mutagenicity/genotoxicity, and there is sufficient evidence that DNA adduct formation and the resulting mutagenic/genotoxic effects are key events in the mode of action of EtO carcinogenicity; d) evidence of chromosome damage in humans exposed to EtO, supporting the inference that the same mode of action for EtO carcinogenicity is operative in humans.

1. Do the available data and discussion in the draft document support the hazard conclusion that EtO is carcinogenic to humans based on the weight-of-evidence descriptors in EPA's 2005 Guidelines for Carcinogen Risk Assessment? In your response, please include consideration of the following:

1.a. Qualitative Characterization of Epidemiology Data

EPA concluded that the epidemiological evidence on EtO carcinogenicity was strong, but less than completely conclusive. Does the draft document provide sufficient description of the studies and transparent analysis of the data used to assess the carcinogenic hazard of EtO to humans? Please comment on the EPA's characterization of the body of epidemiological data reviewed. Considerations include:

a) the consistency of the findings, including the significance of differences in results using different exposure metrics, b) the utility of the internal (based on exposure category) versus external (e.g., SMR and SIR) comparisons of cancer rates, c) the magnitude of the risks, and d) the strength of the epidemiological evidence.

A majority of the Panel agreed with the conclusion in the draft document that the available evidence supports a descriptor of "Carcinogenic to Humans" but some of Panel members concluded that the descriptor "Likely to be Carcinogenic to Humans" was more

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 appropriate. The consensus of the Panel was that the epidemiological data regarding ethylene
2 oxide carcinogenicity did not provide convincing evidence of a causal association between
3 human exposure and cancer. The differing views as to the appropriate descriptor for ethylene
4 oxide were based on whether all of the requirements for designation as “Carcinogenic to
5 Humans” in the absence of convincing epidemiological evidence were met. Panel members
6 favoring a descriptor of “Carcinogenic to Humans” found the epidemiological evidence for
7 an association between ethylene oxide exposure and cancer to be adequate, albeit not strong
8 enough to assert causality. Other Panel members found the epidemiological evidence to be
9 weak, lacking consistency across multiple studies, and they concluded that the data were
10 currently insufficient to conclude that key precursor events were observed in humans.
11

12 The Panel believes that the document would be improved by a better introduction to the
13 hazard characterization section, including a brief description of the information that will be
14 presented. EPA has provided a comprehensive review (when the Draft Assessment as a
15 whole is considered) of the existing epidemiologic evidence relevant to ethylene oxide and a
16 fair, transparent, and critical assessment of this evidence for purposes of classifying EtO as a
17 human carcinogen. Presentation of the epidemiologic evidence would be strengthened by
18 including a summary figure and/or table at the beginning of section 3.0. In particular, the
19 authors should include the material now provided in Appendix A within the main body of the
20 Draft Assessment. These tables should also provide clearer information on the observed
21 endpoints, in particular any information regarding cancer type within the broad category of
22 lymphohematopoietic cancers.
23

24 Based on this review, the Agency’s assessment that the evidence is “strong but less than
25 completely conclusive” is supported although a characterization of the epidemiologic
26 evidence as “strong” is questionable. This ambiguity and the “less than completely
27 conclusive” assessment is appropriate given the uncertainties and inconsistencies in the
28 occupational epidemiology as is accurately summarized on page 11 of the Draft Assessment
29 “3.1.1. Conclusions Regarding the Evidence of Cancer in Humans.” EPA has both
30 appropriately applied the Hill criteria to assess causality and correctly interpreted their
31 application to the existing data. EPA’s determination of EtO as a human carcinogen is robust
32 in that this conclusion is sustained by the largest and highest quality study (i.e., the NIOSH
33 study) under a variety of approaches to exposure classification. EPA appropriately identifies
34 Steenland et al. as the critical study for establishing human carcinogenicity. We agree with
35 EPA in their reliance on “internal” estimates of cancer rates rather than “external”
36 comparisons (SMR, SIR) due to well recognized limitations to the latter method of analysis.
37 The Draft Assessment appropriately characterizes the magnitude of the risk associated with
38 EtO as “weak”. This finding is well substantiated by the epidemiologic evidence where a
39 relatively small number of excess cancers are found above background even among highly
40 exposed individuals. A more comprehensive discussion with additional perspective can be
41 provided by comparing EtO’s risk to other similar carcinogens such as benzene, 1,3-
42 butadiene, and/or formaldehyde.
43

44 The EPA’s reliance on the NIOSH studies in providing a robust basis for assessment is
45 well justified based on the sample size and available quantitative exposure data. In this

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 study, the strongest exposure response associations were found with log cumulative exposure
2 rather than average or peak exposure. Such a basis for exposure classification is well
3 supported for a chronic effect such as cancer. The Draft Assessment describes both the
4 internal and external cancer rates reported within the literature. This is appropriate both for
5 providing an accurate summary and for addressing the different dimensions of EPA's
6 evaluation, i.e. strength of evidence and unit risk estimate. There was a strong sense among
7 the Panel that the EPA's risk characterization could be improved by additional analyses of
8 the raw NIOSH data, taking into account the individual exposure data in the dose-response
9 model

10 11 **1.b. Relevant Additional Key Studies**

12
13 **Are there additional key published studies or publicly available scientific reports that**
14 **are missing from the draft document and that might be useful of the discussion of the**
15 **carcinogenic hazard of EtO?**
16

17 Although the Draft Assessment generally provides a clear and concise summary of
18 the literature regarding EtO, the Panel identified two areas that deserve a more expansive
19 treatment. First, endogenous production of EtO results in some measure of background DNA
20 adducts and this issue should be addressed more fully in the document. The presentation of
21 data from a single reference (Bolt, 1996) giving background levels of 7-HEG in unexposed
22 humans suggests that (i) these values are the most reliable and (ii) the potential impact of
23 spontaneous hydroxyethylation of DNA by endogenously formed EtO has little to no
24 importance in the estimation of human cancer risk for this chemical. However, it has been
25 known for nearly 20 years that endogenous formation of ethylene and conversion to EtO
26 leads to 2-hydroxyethylation of DNA yielding background levels of 7-HEG in unexposed
27 humans and rodents (Föst et al., 1989; Walker et al., 1992b, 2000; Cushnir et al., 1993;
28 Farmer et al., 1993; van Delft et al., 1993, 1994; Leutbecher, 1995; Bolt et al., 1997; Wu et
29 al., 1999; Zhao et al., 1999). Table V in Walker et al. (2000) lists a series of studies of
30 background levels of these adducts in differing tissues of unexposed humans (see references
31 therein), showing that lower spontaneous levels of 7-HEG have been typically found using
32 more sensitive detection methods than those used in reports cited in Bolt's commentary
33 (1996) (see references therein). In another commentary/review, Farmer and Shuker (1999)
34 suggest that in order to estimate the increase in cancer risk attributable to a given external
35 exposure, it is clearly important to establish and consider background levels of corresponding
36 DNA damage so that the scale of the incremental increase can be calculated. It is mainly for
37 this reason that more sensitive and specific analytical methods have been developed for the
38 measurement of background and EtO treatment-induced levels of 7-HEG than for any single
39 other DNA adduct (supporting references available). Because the levels of background 7-
40 HEG are fairly substantial, and there are no chemical differences in DNA damage by
41 endogenous versus exogenous EtO, the Draft Assessment requires a section considering the
42 potential impact of endogenous versus exogenous EtO exposure that carefully lays out (i)
43 why the current evidence of background levels of 2-hydroxyethylation of DNA does not
44 constitute a threshold and (ii) whether the magnitude and variability in endogenous EtO-

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 induced damage may overwhelm any contribution from exogenous EtO exposure (other than
2 some acute high-dose exposure).
3

4 Second, a more comprehensive discussion of the production of DNA adducts by EtO
5 exposure would be appropriate. For the last paragraph of section 3.3.1 (page 21), a report by
6 Dan Segerbäck (1990) showed that treatment of calf thymus DNA with ¹⁴C-labelled EtO
7 resulted in the formation of N7-HEG, N3-HEA, and O⁶-HEG at a ratio of 200:8.8:1. The
8 Draft Assessment suggested that this ratio of DNA adducts was found in a study of EtO-
9 exposed rats by Zhao et al. (1997); however, N7-HEG was the only product of EtO-induced
10 hydroxyethylation measured in this study. Instead, Walker et al. (1992b) found that the ratio
11 of the steady-state concentrations of 7-HEG, 3-HEA, and O⁶-HEG was 300:1.2:1 following
12 repeated exposures of rats to EtO, indicating that 3-HEA and O⁶-HEG do not accumulate in
13 vivo to the levels predicted by the in vitro ratios of these adducts and 7-HEG. The same
14 misquoting of Zhao et al., (1997) about the ratio of these three DNA adducts is present
15 beginning on the last line of page 21 of the Draft Assessment.
16

17 Finally, some Panel members supported the inclusion of the cancer bioassay results
18 for ethylene exposure and believed they were relevant and should be discussed in the Draft
19 Assessment. However, others on the Panel were less enthusiastic about this addition and felt
20 that, were the ethylene results to be included, a careful discussion of the caveats to their
21 interpretation relative to EtO carcinogenicity would be essential. The rationale for including
22 the bioassay results for inhalation exposure of F344 rats to ethylene (Hamm et al., 1984) is as
23 follows. There were no treatment- or dose-dependent increases in the induction of neoplasms
24 following 2 years of exposure to 0, 300, 1000, or 3000 ppm ethylene, suggesting that the
25 levels of in vivo formation of EtO during exogenous exposures to ethylene were insufficient
26 to have carcinogenic effects. In vivo metabolism of ethylene at high exogenous exposures
27 (>1000 ppm) is saturated and EtO is formed at the highest rate possible in the rat, with
28 ethylene concentrations higher than 1000 ppm corresponding to exogenous exposure to
29 approximately 6 ppm EtO based upon N7-(2-hydroxyethyl)valine values and a two-
30 compartment model (Bolt and Filser, 1987; Czanády et al., 2000; Walker et al., 2000).
31 Measurements of N7-(2-hydroxyethyl)guanine (7-HEG) adduct levels in rats exposed to
32 ethylene or directly to EtO indicate that 3000 ppm ethylene exposures yield equivalent EtO
33 levels of 6.4 to 9.5 ppm in various tissues except for liver (Walker et al., 2000). The
34 resulting reactions with nucleic acids and proteins following in vitro or in vivo exposures to
35 EtO are purely chemical in nature. In terms of potential differences in the nature and/or the
36 degree of DNA damage produced by hydroxyethylcarbonium ions resulting from (i) in vivo
37 conversion of endogenously formed ethylene to EtO, (ii) in vivo formation of EtO following
38 exogenous exposure to ethylene, and (iii) exogenous exposures to EtO – there is no
39 biological, chemical, or theoretical basis for believing that hydroxyethylation arising from
40 these three different sources is different and imposes more or less genetic risk. Furthermore,
41 EtO arising from metabolism of endogenous/exogenous ethylene or from exogenous EtO
42 exposures is rapidly and evenly distributed to all tissues (except for testis) in vivo (Wu et al.,
43 1999; Walker et al., 2000). Thus, under standard cancer bioassay conditions using 63 to 80
44 rats per group, the ethylene equivalent of approximately 6 ppm EtO appears to be below the
45 limit of detection for a tumor response over the spontaneous background in the F344 rat.

1
2 For the first paragraph of section 3.3.2.1, increased frequencies of *Hprt* gene
3 mutations were also observed in lymphocytes of rats at concentrations of EtO used in cancer
4 studies with this species (Tates et al., 1999; van Sittert et al., 2000; Walker et al., 2000).
5 Likewise, for the sentence beginning on page 24, line 27, the underlined changes are
6 suggested: “Increases in the frequency of gene mutations in the lung, in T-lymphocytes, in
7 bone marrow, and/or in the testes have been observed in transgenic mice and in rats exposed
8 to EtO by inhalation.....” For the remainder of this section, it should be noted that *Hprt*
9 refers to the rodent gene while *HPRT* is reserved for the human counterpart in discussing
10 data about this reporter gene.
11

12
13 **Relevant references which were not included in the draft on Evaluation of the**
14 **Carcinogenicity of EtO:**
15

16 Albertini, R.A., and Sweeney, L.M. (2006) Propylene oxide: genotoxicity profile of a rodent
17 nasal carcinogen. *CRC Toxicology*, in press.
18

19 Applegren, L.E., Eneroth, G., Grant, C., Lanström, L.E., and TENGHAGEN, K. (1978) Testing
20 of ethylene oxide for mutagenicity using the micronucleus test in mice and rats. *Act*
21 *Pharmacol. Toxicol.* 43: 69-71.
22

23 Bastlová, T., Andersson, B., Lambert, B., and Kolman, A. (1993) Molecular analysis of
24 ethylene oxide-induced mutations at the HPRT locus in human diploid fibroblasts.
25 *Mutat. Res.* 287: 283-292.
26

27 Bolt, H.M. and Filser, J.G. (1987) Kinetics and disposition in toxicology. Example:
28 carcinogenic risk estimate for ethylene. *Arch. Toxicol.* 60: 73-76.
29

30 Conan, R.A., Waggy, G.T., Spiegel, M.H., and Berglund, R.L. (1979) Study of the
31 mutagenic action of ethylene oxide, ethylene glycol, and 2-chloroethanol residues in
32 plastic material sterilized by ethylene oxide. *Ann. Falsif. Expert. Chim.* 72: 141-151.
33

34 Eisenbrand, G., Muller, N., Denkel, E., and Sterzel, W. (1986) DNA adducts and DNA
35 damage by antineoplastic and carcinogenic N-nitrosocompounds. *J. Cancer Res. Clin.*
36 *Oncol.* 112: 196-204.
37

38 Farmer, P.B., Bailey, E., Naylor, S., Anderson, D., Brooks, A., Cushnir, J., Lamb, J.H.,
39 Sepai, O., and Tang, Y.-S. (1993) Identification of endogenous electrophiles by means
40 of mass spectrometric determination of protein and DNA adducts. *Environ. Health*
41 *Perspect.* 99: 19-34.
42

43 Farmer, P.B., and Shuker, D.E.G. (1999) What is the significance of increases in background
44 levels of carcinogen-derived protein and DNA adducts? Some considerations for
45 incremental risk assessment. *Mutat. Res.* 424: 275-286.

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

- 1 Farooqi, Z., Tornqvist, M., Ehrenberg, L., and Natarajan, A.T. (1993) Genotoxic effects of
2 ethylene oxide and propylene oxide in mouse bone marrow cells. *Mutat. Res.* 299: 223-
3 228.
4
- 5 Fomenko, V.N., Strekalova, E. Ye (1973) The mutagenic effect of some industrial toxins as a
6 function of concentration and exposure time. *Toksikol Nov Prom Khim Veshchestv* 13:
7 51-57.
8
- 9 Golberg, L. (1986) Hazard Assessment of Ethylene Oxide. CRC Press, Boca Raton, FL, pp
10 3-7.
11
- 12 Hamm, T.E. Jr., Guest, D., and Dent, J.G. (1984) Chronic toxicity and oncogenicity bioassay
13 of inhaled ethylene in Fischer-344 rats. *Fund. Appl. Toxicol.* 4: 473-478.
14
- 15 Hurst, D.T. (1980) An Introduction to the Chemistry and Biochemistry of Pyrimidines,
16 Purines, and pteridines. Wiley, New York, pp 5-8.
17
- 18 Jenssen D., and Ramel, C. (1980) The micronucleus test is part of a short-term mutagenicity
19 test program for the prediction of carcinogenicity evaluated by 143 agents test. *Mutat.*
20 *Res.* 75: 191-202.
21
- 22 Kligerman, A.D., Erexson, G.L., Phelps, M.E., and Wilmer, J.L. (1983) Sister-chromatid
23 exchange induction in peripheral blood lymphocytes of rats exposed to ethylene oxide
24 by inhalation. *Mutat. Res.* 120:37-44.
25
- 26 Lambert, B., Andersson, B., Bastlova, T., Hou, S.-M., Hellgren, D., and Kolman, A. (1994)
27 Mutations induced in the hypoxanthine phosphoribosyl transferase gene by three urban
28 air pollutants: acetaldehyde, benzo[a]pyrene diolepoxide, and ethylene oxide. *Environ.*
29 *Health Perspect* 102 (Suppl. 4): 135-138.
30
- 31 Lin, J.-S., Chuang, K.-T., Huang, M.-S., and Wei, K.-M., (2007) Emission of ethylene oxide
32 during frying of foods in soybean oil. *Food and Chemical Toxicology* 45: 568–574.
33
34
- 35 Lorenti Garcia, C. Darroudi, F., Tates, A.D., and Natarajan, A.T. (2001) Induction and
36 persistence of micronuclei, sister-chromatid exchanges and chromosomal aberrations in
37 splenocytes and bone-marrow cells of rats exposed to ethylene oxide. *Mutat. Res.* 492:
38 59-67.
39
- 40 Marsden DA, Jones DJ , Lamb JH, Tompkins EM, Farmer PB, Brown K (2007)
41 Determination of endogenous and exogenously derived N7-(2-hydroxyethyl)guanine
42 adducts in ethylene oxide-treated rats. *Chem Res Toxicol* 20:290-299.
43

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

- 1 Ong, T., Bi H.K., Xing, S., Stewart, J., and Moorman, W. (1993) Induction of sister
2 chromatid exchange in spleen and bone marrow cells of rats exposed by inhalation to
3 different dose rates of ethylene oxide. *Environ. Mol. Mutagen.* 22: 147-151.
4
- 5 Ribeiro, L.R., Tabeto-Gay, M.N., Salvadori, D.M., Pereira, C.A., and Becak, W. (1987)
6 Cytogenetic effects of inhaled ethylene oxide in somatic and germ cells of mice. *Arch.*
7 *Toxicol.* 59: 332-335.
8
- 9 Rusyn, I., Asakura, S., Li, Y., Kosyk, O., Koc, H., Nakamura, J., Upton, P.B., and Swenberg,
10 J.A. (2005) Effects of ethylene oxide and ethylene inhalation on DNA adducts,
11 apurinic/apyrimidinic sites and expression of base excision DNA repair gene in rat brain,
12 spleen, and liver. *DNA Repair (Amst.)* 4: 1099-1110.
13
- 14 Segerbäck, D. (1990) Reaction products in hemoglobin and DNA after in vitro treatment
15 with ethylene oxidized and *N*-(2-hydroxyethyl)-*N*-nitrosourea. *Carcinogenesis* 11:307-
16 312.
17
- 18 Strelkova, E. Ye, Chirkova, E.M., and Golubovich, E. (1975) Mutagenic action of ethylene
19 oxide on sex and somatic cells in male white rats. *Toksikol Nov Prom Khim*
20 *Veshchestv* 14: 11-16.
21
- 22 Tates, D., van Dam, F. J., Natarajan, A. T., van Teylingen C. M.M., de Zwart, F. A.,
23 Zwinderman, A. H., van Sittert, N. J., Nilsen, A., Nilsen, O. G., Zahlsen, K.,
24 Magnusson, A.-L., and Tornqvist, M. (1999) Measurement of *HPRT* mutations in
25 splenic lymphocytes and haemoglobin adducts in erythrocytes of Lewis rats exposed to
26 ethylene oxide. *Mutation Research* 431: 397-415
27
- 28 Van Delft J.H.M., van Winden M.J.M., van den Ende, A.M.C., and Baan R.A. (1993)
29 Determining N7-alkylguanine adducts by immunochemical methods and HPLC with
30 electrochemical detection: application in animal studies and in monitoring human
31 exposure to alkylating agents. *Environ. Health Perspect.* 99: 25-32.
32
- 33 Van Sittert, N.J., Boogaard, P.J., Natarajan, A.T., Tates A.D., Ehrenberg, L.G., and
34 Tornqvist, M.A. (2007) Formation of DNA adducts and induction of mutagenic effects
35 in rats following 4 weeks inhalation exposure to ethylene oxide as a basis for cancer
36 risk assessment. *Mutation Research* 447: 27-48.
37
- 38 Walker, V.E., Wu, K.-Y., Upton, P.B., Ranasinghe, A., Scheller, N., Cho, M.-H., Vergnes,
39 J.S., Skopek, T.R., and Swenberg, J.A. (2000) Biomarkers of exposure and effect as
40 indicators of potential carcinogenic risk arising from *in vivo* metabolism of ethylene to
41 ethylene oxide. *Carcinogenesis*, 21: 1661-1669.
42
43
44
45

1.c. Mode of Action**Do the available data and discussion in the draft document support the mode of action conclusions?**

The Panel agrees with the conclusion in the draft assessment that the available data strongly support the action of EtO as a genotoxic agent producing DNA adducts as well as cytogenetic and small-scale mutagenic effects. However, a more careful discussion of the sequence of events that are presumed to lead to EtO-induced mutagenesis is warranted. In the Draft Assessment, the description of the events leading to gene mutations and chromosome damage presume that 7-HEG and *N*-alkylated bases are indirectly responsible, or primarily responsible, for genetic changes. The section on the mode of action does not consider any other possibilities to explain the genotoxicity of EtO, which include (but are not limited to) the potential consequences of (i) formation of minor promutagenic adducts, (ii) hydroxyethylation of the DNA backbone, and (iii) the formation of secondary reactive species including reactive oxygen species. The sentence beginning on line 4 of page 22 states that “HEG adducts result in various types of cytogenetic damage, including gene mutations, which have been observed in mice and rats”. However, there is currently limited evidence to directly support this statement.

As discussed in a recent review by Albertini and Sweeney (2006), N7-alkylguanine adducts formed from small epoxides such as EtO and propylene oxide do not cause distortion of the double helix and do not interfere with hydrogen bonding; rather, they are hypothesized to result in mutation via loss of N7-alkylguanine via depurination or the action of DNA glycosylases, leaving an apurinic site in the DNA. The action of apurinic endonuclease indeed creates a DNA single-strand break which, if unresolved, can lead to DNA double-strand breaks. Furthermore, depurination of N7-alkylguanine can result in preferential insertion of an adenine (according to the A-rule) or another base leading to mispairing/mutations. Based upon the initial mutational spectra data for EtO in mice (Walker and Skopek, 1993), it was hypothesized that formation of apurinic (AP) sites might be involved in the mutagenesis of EtO. In order for these mutagenic events to occur at a rate sufficient to result in an EtO-induced changes in mutational spectra (including increases in double-strand breaks and changes in mutant fractions for point mutations), then accumulation of AP sites arising from high levels of 7-HEG would be expected to occur over time. A study was recently completed to test the hypothesis that EtO exposure results in the accumulation of AP sites and induces changes in the expression of genes for base excision DNA repair, predisposing to point mutations and chromosomal aberrations in F344 rats exposed by inhalation for 4 weeks to 0 or 100 ppm EtO, or 0 to 3000 ppm ethylene, (Rusyn et al., 2005). The resulting data demonstrated that DNA damage induced by exposure to EtO is repaired without accumulation of AP sites, and that the mechanisms proposed above play a minor role in the mutagenicity of EtO. The same conclusions would apply to the accumulation of 3-HEA formed in minor amounts in EtO-exposed rats (Walker et al., 1992b), and the induction of strand breaks or point mutations at A:T base pairs. Rusyn et al. (2005) have suggested that the mutagenic effects of EtO were likely to be the result of minor promutagenic adducts, such as O⁶-HEG, N1-HEA adenine, or possibly ring-opened 7-HEG.

1
2 Drs. Lars Ehrenberg and Timothy Fennell have independently proposed that EtO may
3 induce strand breaks and chromosomal alterations via 2-hydroxyethylation of the DNA
4 backbone. 2-Hydroxyethylation of phosphate groups introduces extreme instability into the
5 sugar-phosphate backbone because the resulting phosphotriester breaks down through a
6 dioxaphospholane ring intermediate (Eisenbrand et al., 1986). This alternative mechanism
7 for EtO-induced strand breaks and chromosomal damage is not mentioned in the Draft
8 Assessment.
9

10 In summary, the overall genetic toxicology data strongly support the consistent action
11 of EtO as a relatively weak mutagen and clastogen, but the underlying mechanisms for its
12 mode of action as a genotoxin are not known with a high degree of certainty. The paucity of
13 knowledge about the fundamental ways in which EtO acts to induce large- and small-scale
14 mutations is not reflected in the mode-of-action section; rather this section is presented as if
15 there is a good basic understanding (which does not currently exist).
16

17 **1.d. Hazard Characterization**

18
19 **Does the hazard characterization discussion for EtO provide a scientifically-balanced**
20 **and sound description that synthesizes the human, laboratory animal, and supporting**
21 **(e.g., *in vitro*) evidence for human carcinogenic hazard?**
22

23 While some members of the Panel found the hazard characterization section of the
24 Draft Assessment to be satisfactory, a majority expressed concerns that this section did not
25 achieve the necessary level of rigor and balance. As discussed above, a majority of Panel
26 members agreed with the overall characterization of EtO as a human carcinogen. However, a
27 critical issue in this characterization, in particular in the face of epidemiological data that are
28 not strongly conclusive, is whether the precursor events leading to cancer in animals are
29 observed in humans at the levels to which they are exposed to EtO.
30

31 The mode of action for EtO carcinogenicity involves the key events of DNA
32 alkylation and the induction of point mutations and/or chromosomal changes. Evidence for
33 genotoxicity of EtO in humans is largely based on cytogenetic analyses. The frequency of
34 cells with chromosomal aberrations and micronuclei in peripheral blood cells are two of the
35 most accepted cytogenetic biomarkers used in human population studies because they were
36 the first indicators of effect shown to be early predictors of cancer risk. However, the
37 micronucleus data in EtO-exposed humans are weak, with very small increases reported, and
38 the abundant data on chromosomal aberrations in EtO-exposed people have not
39 demonstrated, with confidence, the occurrence of stable chromosome changes leading to
40 mutations. As indicated at the bottom of page 20 of the Draft Assessment, chromosome
41 painting/FISH are needed to detect and quantify stable chromosomal aberrations, which
42 would provide more conclusive evidence for classifying EtO as a human carcinogen. A
43 problem in the hazard characterization in the Draft Assessment is the lack of an adequate
44 review of the cytogenetic data for EtO in exposed rodents and head-to-head comparisons to
45 corresponding data in humans. The sections concerning sister chromatid exchanges (SCEs)

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 (3.3.2.2) and chromosomal aberrations (3.3.2.3) in the Supporting Evidence present only data
2 from human studies and overlook contradictory or equivocal findings from studies of EtO-
3 exposed rodents. Furthermore, there is no discussion of findings related to micronuclei in
4 humans or rodents in the Supporting Evidence section. In brief, several studies have shown
5 that repeated exposures of rats to high concentrations of EtO induces dose-related increases
6 in SCEs (Kligerman et al., 1982; Ong et al., 1993; van Sittert et al., 2000; Lorenti Garcia et
7 al., 2001). Treatment of rats and mice with high acute doses of EtO by i.p./i.v. injection or
8 oral dosing (i.e., routes of exposure not relevant to humans) also caused increases in the
9 frequencies of micronuclei or chromosomal aberrations (Strekalova et al., 1971; Applegren
10 et al., 1978; Conan et al., 1979; Jensen and Ramel, 1980; Farooqui et al., 1993). In contrast,
11 following inhalation exposures (i.e., a route of exposure relevant to humans), no increases in
12 the frequencies of micronuclei or chromosomal aberrations were found in peripheral
13 blood/splenic lymphocytes from rats exposed at concentrations of 50 to 450 ppm EtO for 1
14 or 3 days (Kligerman et al., 1982) or 50 to 200 ppm EtO for 4 weeks (5 days/week, 6 h/day)
15 (van Sittert et al., 2000; Lorenti Garcia et al., 2001). Furthermore, two studies showed that 4
16 weeks of exposure of rats to 200 ppm EtO failed to cause an increase in translocations (van
17 Sittert et al., 2000; Lorenti Garcia et al., 2001) (e.g., the % translocation in controls and 200
18 ppm rats were 0.1% and 0.09%, respectively, in the latter study). In the study by van Sittert
19 et al. (2000), the authors concluded that “The absence of effects on reciprocal translocations
20 (assessed by FISH) demonstrates that 4 weeks of inhalation exposure to EO at high levels
21 does not produce genetically transmissible chromosome aberrations in the rat.” A single
22 study reported that repeated exposures of mice at 200 to 600 ppm EtO for two weeks induced
23 chromosomal aberrations in bone marrow cells (Ribeiro et al., 1987), but no studies have
24 been performed to assess whether this chemical causes transmissible chromosome
25 aberrations in somatic cells in this species.

26
27 In contrast to lack of data supporting induction of chromosome aberrations and
28 reciprocal translocations at EtO concentrations used in rodent carcinogenicity studies of this
29 chemical, there are unequivocal data from three research groups (cited reports by Les Recio,
30 Ad Tates, and Vernon Walker) showing that EtO causes dose-related increases in point
31 mutations in multiple tissues of mice and rats exposed by inhalation to 50, 100, or 200 ppm
32 EtO, or concentrations used in the cancer bioassays of EtO, as well as in oncogenes and
33 tumor suppressor genes of various EtO-induced cancers in the mouse (Houle et al., 2006;
34 Hong et al., 2007). In these rodent studies using the *Hprt* and/or *lacI* reporter genes, EtO was
35 consistently a weak point mutagen. However, as noted in the Draft Assessment, studies of
36 the induction of *Hprt* mutations in EtO-exposed humans have been inconclusive.

37
38 Thus, studies of both humans and rodents exposed to EtO have yielded evidence
39 consistent with the genotoxic mode of action of EtO, but different types of genetic alterations
40 are demonstrated in the two species.

Charge Question 2- Dose-Response Analysis

The Agency's assessment describes the derivation of inhalation unit risk estimates for cancer mortality and incidence based on the human data. An EC_{01} of $44 \mu\text{g}/\text{m}^3$ (0.024 ppm) was calculated using a life-table analysis and linear modeling of the categorical Cox regression analysis results for excess lymphohematopoietic cancer mortality in males reported in a high-quality occupational epidemiologic study (Steenland et al., 2004). Linear low-dose extrapolation from the LEC_{01} yielded a lifetime extra cancer mortality unit risk estimate of 5.0×10^{-4} per $\mu\text{g}/\text{m}^3$ (0.92 per ppm) of continuous EtO exposure. According to EPA's assessment, applying the same linear regression coefficient and life-table analysis to background male lymphohematopoietic cancer *incidence* rates yielded an EC_{01} of $24 \mu\text{g}/\text{m}^3$ (0.013 ppm) and a preferred lifetime extra cancer unit risk estimate of 9.0×10^{-4} per $\mu\text{g}/\text{m}^3$ (1.6 per ppm). The preferred estimate was greater than the estimate of 5.0×10^{-4} per $\mu\text{g}/\text{m}^3$ (0.91 per ppm; $EC_{01} = 44 \mu\text{g}/\text{m}^3$) calculated, using the same approach, from the results of a breast cancer incidence study of the same worker cohort (Steenland et al., 2003), and was recommended as the potency estimate for Agency use.

According to the Agency's assessment, the weight of evidence supports a mutagenic mode of action for EtO carcinogenicity. The Draft Assessment then concludes that, in the absence of chemical-specific data on early-life susceptibility, an increased early-life susceptibility should be assumed and the age-dependent adjustment factors (ADAFs) should be applied, in accordance with EPA's *Supplemental Guidance for Assessing Susceptibility From Early-Life Exposure to Carcinogens*, hereinafter referred to as "EPA's Supplemental Guidance" (U.S. EPA, 2005b). Applying the ADAFs to the unit risk estimate of 9.0×10^{-4} per $\mu\text{g}/\text{m}^3$ yields an adjusted full lifetime unit risk estimate of 1.5×10^{-3} per $\mu\text{g}/\text{m}^3$, and the commensurate lifetime chronic exposure level of EtO corresponding to an increased cancer risk of 10^{-6} is $0.0007 \mu\text{g}/\text{m}^3$. [Note that for less-than-lifetime exposure scenarios (or for exposures that vary with age), the unadjusted (adult-based) potency estimate of 9.0×10^{-4} per $\mu\text{g}/\text{m}^3$ should be used, in conjunction with the ADAFs as appropriate, in accordance with EPA's Supplemental Guidance.]

In the Agency's assessment, unit risk estimates were also derived from the three chronic rodent bioassays for EtO reported in the literature. These estimates, ranging from 2.2×10^{-5} per $\mu\text{g}/\text{m}^3$ to 4.6×10^{-5} per $\mu\text{g}/\text{m}^3$, are about an order of magnitude lower than the estimates based on human data [unadjusted for early-life susceptibility]. The Agency takes the position that human data, if adequate data are available, provide a more appropriate basis than rodent data for estimating population risks (U.S. EPA, 2005a), primarily because uncertainties in extrapolating quantitative risks from rodents to humans are avoided. Although there is a fairly sizable difference between the rodent- and human-based estimates, the assessment infers that the similarity between the unit risk estimates based on the male lymphohematopoietic cancer and the female breast cancer results increases confidence in the use of the unit risk estimate based on the male lymphohematopoietic cancer results. According to the Agency assessment, the unit risk estimates were developed for environmental exposure levels and are not necessarily applicable to higher-level occupational exposures, that appear to be subject to a different exposure-response relationship. However, occupational exposure levels are of concern to EPA when EtO is used as a pesticide (e.g.,

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

fumigant for spices). Therefore, it is appropriate that EPA presents risk estimates for occupational exposure scenarios.

2. Do the available data and discussion in the draft document support the approaches taken by EPA in its derivation of cancer risk estimates for EtO? In your response, please include consideration of the following:

2.a. Selection of Epidemiology Studies

EPA concluded that the epidemiological evidence alone was strong but less than completely conclusive (although EPA characterized the total evidence - from human, laboratory animal, and in vitro studies - as supporting a conclusion that EtO as "carcinogenic to humans"). Is the use of epidemiological data, in particular the Steenland et al. (2003, 2004) data set, the most appropriate for estimating the magnitude of the carcinogenic risk to humans from environmental EtO exposures? Are the scientific justifications for using this data set transparently described? Is the basis for selecting the Steenland et al. data over other available data (e.g., the Union Carbide data) for quantifying risk adequately described?

The Panel agreed that the epidemiological evidence is less than completely conclusive. The data are somewhat consistent in showing a weak to moderate excess carcinogenic response. It is not unusual for epidemiological evidence to be strong but in and of itself not provide conclusive evidence of causation. It is appropriate in light of conclusive evidence in animals to use sound human epidemiological studies to determine the dose response even though in and of themselves these studies may not provide conclusive evidence of carcinogenicity.

The Panel agreed that the NIOSH retrospective cohort study with observations on in excess of 18,000 workers from 13 sterilizing facilities is the best single source of data for determining the dose-response relationship for evaluating the risk of low level EtO exposure in human populations (Steenland et al, 2004).

As a single source, the epidemiological data for the NIOSH cohort has the following distinct advantages:

- 1) A large (18,000+) sample of workers with long periods of exposure to EtO;
- 2) A roughly 55%/45% female to male gender ratio, similar to the general population;
- 3) Multiple distinct facilities with worker exposure estimates. (Facility intra-class correlation is never considered in any of the models applied to the NIOSH data);
- 4) Limited coincidental exposure in the occupational cohort to other compounds, e.g. ethylene dichloride, that might confound the interpretation of the relationship of EtO exposure to cancer outcomes.

1
2 5) Careful mortality follow-up using multiple sources; and finally

3
4 6) Continuity of the investigators who have been building and analyzing the data set.

5
6 A primary disadvantage of the NIOSH data, common to all retrospective
7 epidemiological data, is the need to apply a model to estimate the profile (time, intensity) of
8 individuals' exposure to EtO (Hornung, et al., 1994). The model of EtO exposure over time
9 is needed to support the use of different exposure metrics, e.g. cumulative (time integrated),
10 peak, duration. Random errors in estimating exposures are certainly present and systematic
11 bias resulting from errors in model inputs or model misspecification are certainly also
12 present to some extent. Ideally, estimation biases are small relative to the variance of the
13 predictions and the assigned exposure profiles result in acceptable classifications of
14 individual exposure levels (see below). Given the importance the estimated exposures to the
15 use of these data in ultimately modeling the dose-response relationship, the Panel noted
16 several important features of the NIOSH exposure estimation model and the exposure
17 predictions for individual NIOSH cohort members.

18
19 The worker exposure observations used to fit the model were not a random sample
20 (effect unknown) of workers or work environments but were designed to represent the
21 typical range of exposure conditions that occur in the contemporary work place. A total of
22 2350 full-shift charcoal tube measurements were collected from workers in twelve plants.
23 By design, the observations were distributed across workers involved in eight exposure
24 activity types (e.g. sterilizer area, production, maintenance) and five product types (e.g. spore
25 strips, plastics, etc.). In addition to these two main effects, the multivariate regression model
26 for predicting exposures for the NIOSH cohort workers includes additional covariates for age
27 of product, year (of exposure), and size and ventilation characteristics of the work area. A
28 random sub-sample of observations of the worker measurements was set aside as a cross-
29 validation sample for purposes of evaluating the predictive potential of the fitted model.
30 The final model produced an R^2 to the cross-validation exposure measurements (cross
31 validation sample) of 0.85. There was consensus among the Panel that the exposure model
32 development for the NIOSH data was conducted in a rigorous fashion and it would be
33 difficult to improve on the exposure estimates generated by the NIOSH exposure
34 measurement study (Griefe et al., 1988, Steenland et al., 1987).

35
36 In its discussion of the predicted exposure measures in NIOSH cohort data, the Panel
37 focused in some detail on the role of chronological time in the prediction of annual exposures
38 for the individual cohort members. From Table VI of Hornung et al. (1994), the year in
39 which the exposure occurred is highly predictive of the exposure concentration. Quoting
40 from the paper, "We had hoped that some combination of engineering controls would
41 eliminate the need for including calendar year in the model, However, no combination of
42 variables could be found to allow removal of calendar year from the model. We attributed
43 this finding to calendar year acting as a surrogate for improvement in work practices due to
44 increased awareness of the potential health effects of ETO". The effect of chronological
45 time is highly significant and quadratic--- $-0.446 \times (\text{year}-82)$ and $0.062 \times (\text{year}-82)^2$. The

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 model-based assignment of exposures to individuals in the NIOSH cohort truncates this
2 highly significant time effect on exposure (quadratic) at 1978. That is, all exposures for
3 work years prior to 1978 receive the same contribution to modeled exposure as in 1978—the
4 year at which the trend in exposures is at a maximum for the quadratic time effect. The
5 reason for assigning all pre-1978 exposures to the 1978 level is that prior to that time data on
6 general work place exposures was scarce (7 activity x product combination mean exposures
7 based on 23 individual samples collected in 1976-1978).
8

9 Regarding the handling of time in modeling annual exposures for individual NIOSH
10 cohort members, the Panel's concern is less on the modeling decision but rather on how this
11 estimation decision may interact with subsequent dose response model fitting in which the
12 exposure metric is itself a function of time. For example, the 1978 truncation point is very
13 close to the analysis censoring exposure point of t-15, or t-20 for the Steenland et al. (2004)
14 dose response models that use time lagged exposure as the independent variable. Does
15 introducing the lag into the cumulative exposure measurement alter the quality of the
16 effective exposure model since the parameters for non-time factors (e.g. activity type,
17 product type, engineering controls, size of workplace) have been estimated in the presence of
18 a strong and dominant quadratic time trend? The Panel encourages the EPA to investigate
19 potential instability that may result from interaction between the chosen time metric for the
20 dose response model and the treatment of time in the estimated exposure (e.g. log
21 cumulative, exposure with 15 year lag) that is the independent variable in that dose-response
22 model.
23

24 While the advantages of the Steenland data set are described, the Draft Assessment
25 contains no list of the criteria that were utilized to select studies for inclusion in the risk
26 assessment process. For example, a description of what constituted adequate sample size,
27 exposure assessment, minimum length of employment, length of follow-up, lag time for
28 selected outcomes, etc., would be helpful. It is certainly appropriate to critique all available
29 datasets and provide justification for excluding those who did not meet these criteria. While
30 a review of most studies conducted between 1985 (when the last EtO assessment was
31 conducted) and 2004 was included, it was not always clear why some studies were not
32 considered in the process. For example, Steenland's dataset was deemed most appropriate
33 because of the larger sample size (n=18,254), gender diversity (45% male, 55% female), lack
34 of potentially confounding co-exposures, and more developed measures of individual worker
35 exposures. There were disadvantages, e.g., lack of information on age of the cohort
36 members. The authors state that earlier exposures decreased markedly by the mid-1980's.
37 Did the risk of cancer decrease in later time intervals, i.e., what is the risk for workers
38 initiating employment in the 1980's when levels are lower over a similar time period (20
39 years)? Also, age at exposure, an increasingly recognized critical factor in
40 environmental/occupational exposures and adverse health effects, could not be evaluated
41 (e.g., younger workers with similar cumulative exposures may be at different risk than older
42 workers).
43

44 Other cohorts consisted of smaller sample sizes, less precise measures of individual
45 worker's exposure levels, and concurrent chemical exposures. Some of these studies were

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 justifiably omitted from the risk assessment because of sufficient weaknesses in design
2 and/or analysis. However, it seems it would be of value to examine some of these studies to
3 determine the potential for interaction between EtO and other common workplace exposures.
4

5 To summarize, the Panel concurred that the NIOSH cohort is the best single
6 epidemiological data set with which to study the relationship of cancer mortality to the full
7 range of occupational exposures to EtO. That said, the Panel encouraged the EPA to broadly
8 consider all of the epidemiological data in developing its Draft Assessment. In particular, the
9 Panel encourages the EPA to consider the Greenberg et al. (1990) data on cancer outcomes
10 and EtO exposures for 2174 Union Carbide workers at that firms' two Kana Valley, West
11 Virginia facilities (See Teta et al., 1993; Teta et al., 1999).
12

13 The Panel did not believe that it was necessary to use only one study to arrive at a
14 single potency estimate or to limit the assessment to a single modeling approach. Panel
15 members emphasized that the EPA's own cancer risk assessment guidelines support the
16 consideration of the full range of available data as well as alternatives to the default exposure
17 models. Quoting from the EPA's Guidelines for Cancer Risk Assessment,
18

19 Section 1.3, p. 1-8, "[T]hese cancer guidelines view a critical analysis of all of the available
20 information that is relevant to assessing the carcinogenic risk as the starting point from
21 which a default option may be invoked if needed to address uncertainty or the absence of
22 critical information".
23
24

25 2.b. Methods of Analysis

26
27 **Assuming that Steenland et al. (2003, 2004) is the most appropriate data set, is the use**
28 **of a linear regression model fit to Steenland et al.'s categorical results for all**
29 **lymphohematopoietic cancer in males in only the lower exposure groups scientifically**
30 **and statistically appropriate for estimating potential human risk at the lower end of the**
31 **observable range? Is the use of the grouping of all lymphohematopoietic cancer for the**
32 **purpose of estimating risk appropriate? Are there other appropriate analytical**
33 **approaches that should be considered for estimating potential risk in the lower end of**
34 **the observable range? Is EPA's choice of a preferred model adequately supported and**
35 **justified? In particular, has EPA adequately explained its reasons for not using a**
36 **quadratic model approach such as that of Kirman et al. (2004) based? What**
37 **recommendations would you make regarding low-dose extrapolation below the**
38 **observed range?**
39

40 The Panel's discussion of this multi-part question was extensive. To simplify the
41 presentation here, the written discussion is divided into seven segments: 1) linearity vs.
42 nonlinearity in dose response modeling and extrapolation; 2) the linear regression
43 methodology of grouped risk ratios employed in the EPA Draft Assessment; 3) exclusion of
44 high exposure data points; 4) grouping lymphohematopoietic cancers in analysis; 5) using
45 only male data; 6) justification of approach and alternatives; and 7) statistical and

1 computational issues.

2
3 1. Linearity vs. non-linearity of low dose extrapolation
4

5 The Panel was “philosophically” and scientifically divided on the whether low dose
6 extrapolation of risk to environmental EtO exposure levels should be linear (following
7 Cancer Guideline defaults for mutagenic MOA) or whether plausible biological mechanisms
8 argued for a non-linear form for the low dose response relationship. Some Panel members
9 thought that the data on ethylene oxide imply a non-linear response despite a mutagenic
10 mode of action. They encouraged the exploration of the use of non-linear models for low-
11 dose extrapolation, such as the quadratic and linear quadratic. Others thought that non-linear
12 extrapolation was inappropriate given the mutagenic mode of action. After considerable
13 debate, the Panel was unable to arrive at consensus. Therefore the two distinct lines of
14 argument are presented below.
15

16 The Linear Extrapolation Argument: In general a linear no-threshold interpolation to zero
17 for ethylene oxide external exposure is consistent with available information about the
18 mutagenic mode of action in this case. General arguments are that DNA repair and other
19 genomic defense processes (e.g. apoptosis) are not likely to be perfect in the sense of
20 repairing all incremental damage before the next cycle of DNA copying which would
21 otherwise lead to miscoding errors or more extensive chromosome level changes including
22 breakage, recombination, and nondisjunction events. Genomic defense processes have costs
23 to the cell, and some are also known to create their own baseline damage, so that it is highly
24 likely that the extent of the effectiveness of such processes has been subject to an
25 evolutionary optimization that falls short of perfection. Thus, even with background and
26 endogenous exposures there should be some expectation of ongoing equilibrium damage on a
27 cellular stochastic basis. Such equilibrium damage is likely to contribute to the appreciable
28 “background” of cancers of all types that humans suffer. A detailed review of the argument
29 for "low dose linearity" in cancer risk assessment involving a mutagenic mode of action is
30 given by Hattis (2007, Appendix A).
31

32 The Non-linear Low Dose Response Model Argument: Linear extrapolation of risk below
33 the chosen point of departure (POD) to a zero baseline is a conservative assumption, given
34 EtO's reactivity (which will diminish the amount reaching the nucleus), mutagenic mode of
35 action, and that it is generated endogenously. Some repair seems likely and some threshold
36 probably exists. Thus, the human risk estimates at the lower end of the observable range are
37 likely to be exaggerated under a linear extrapolation. Furthermore, a linear model through
38 zero (linear model per se at low doses is acceptable) assumes that other effects of EtO on the
39 development of cancer are insignificant. This seems unlikely given the reactive nature of this
40 compound and thus its ability to affect signaling pathways that may positively and negatively
41 influence the development of cancer. Measuring such effects is problematic, but they must
42 exist and impact the incidence of cancer. Linear regression is for "extra" risk; but this still
43 seems problematic given the endogenous level of EtO and base levels of damage and repair.
44 In other words, is it justified to assume linear above baseline levels? At low doses, a reactive
45 compound like EtO will react with cellular constituents before it ever gets to DNA. Linear

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 defaults are not supported when a framework analysis is done of genotoxicity and this is
2 even more strongly so for clastogenic agents, which are quadratic in dose response (Preston,
3 1999). Swenberg (2007, Appendix C) provides a framework analysis of Genotoxicity and
4 Risk Assessment in support of an argument for a nonlinear low dose response mechanism for
5 EtO.

6
7 At the conclusion of its discussion, the Panel was not in agreement on the linearity vs.
8 non-linearity of the cancer response to EtO exposure levels in: 1) the occupational exposure
9 data used to estimate the point of departure for the low dose extrapolation; and 2) in the form
10 of the model used to extrapolate cancer risk below the POD to a zero or baseline exposure
11 level. With appropriate discussion of the statistical and biological uncertainties, Panel
12 members advocated the consideration of both linear and nonlinear functional forms in the
13 final EtO Risk Assessment. These Panel members pointed out that such an approach was
14 consistent with the latest guidance in the EPA Guidelines for Cancer Risk Assessment.
15 Quoting Section 1.3 p. 1-9, "*Significant risk management decisions will often benefit from a*
16 *more comprehensive assessment, including alternative risk models having significant*
17 *biological support.*"

18 19 2. Linear regression model for categorical data

20
21 The Panel identified several important shortcomings in the linear regression
22 modeling approach used to establish the point of departure for low dose extrapolation of
23 cancer risk due to EtO. Based on its review of the methods and results presented at the
24 January 17,18, 2007 meeting, the Panel was unanimous in its recommendation that the EPA
25 develop its risk models based on direct analysis of the individual exposure and cancer
26 outcome data for the NIOSH cohort. The Panel understands that these data are available to
27 EPA analysts upon request to the CDC/NIOSH. The Panel recognizes the burden that a
28 reanalysis of the individual data places on the EPA ORD staff but given the important
29 implications of the risk assessment, this burden is well justified to achieve the best scientific
30 and statistical treatment of all the available epidemiological data.

31
32 The following paragraphs present the statistical basis for the Panel's assessment of the
33 linear regression model approach and the use of categorized exposure and outcome data.

34
35 The approach described in the Draft Assessment uses a model based on categories
36 defined by cumulative exposure ranges for male subjects in the NIOSH cohort. Steenland et
37 al. identified several models that provide a significant ($p < 0.05$) fit to the exposure data;
38 however, the EPA has elected to use model-based relative rate parameter estimates for
39 categories of 15 year lagged, cumulative exposure. In Steenland, et al. (2004) this model was
40 not one that provided a significant fit to the NIOSH data ($p = 0.15$ for the likelihood ratio test
41 of $\underline{\beta} = \{\beta_1, \beta_2, \beta_3, \beta_4\} = 0$). The use of the weighted least squares regression fit of a linear
42 regression line through the three data points defined by the estimated rate ratios and mean
43 cumulative exposures for the first three exposure categories of the Steenland, et al. 15 year

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

lag, cumulative exposure category model is not a robust application of this technique. The Panel identified four weaknesses in the approach.

a) Model-based dependent variable: The dependent variables are model-based estimates of rate ratios for exposure categories. The rate ratio values used in the weighted least squares regression are derived from a cumulative exposure model (15 year lag) in which the estimated regression parameters in the proportional hazards regression model are not significantly different from 0 at $\alpha=0.05$ ($p=0.15$). In Steenland et al. (2004), the only individually based (proportional hazards) model that fits the data for males in the NIOSH cohort is a model for log of individual exposure through t-15 years.

b) Grouped data regression: The weighted least squares fit applies estimates of variance for the individual rate ratios under that assumption that these inverse weighting corrections correctly adjust for heteroscedasticity of residuals in the underlying regression model. Historically, models for grouped proportions applied adjustments of this type but it is by no means a preferred technique when the underlying individual data are available. The “ecological regression” model per Rothman (1998, Second edition) is subject to bias due to within group heterogeneity of predictors and unmeasured confounders. The heterogeneity in the grouped model involves the range of exposures within the collapsed categories. The unmeasured confounders include variables (other than gender) that affect the potency of exposure or may have produced gross misclassification based on the original exposure model estimation for the individual (Hornung, et al., 1994).

c) The model fitting does not conform exactly to the Rothman (1986) procedure:

The 1998 (Second edition) of Rothman (Rothman and Greenland, 1998) describes the technique for estimating this risk from grouped data in Chapter 23. In that updated version of the original monograph the model that is fitted is:

$$Expected(Rate | Exposure) = \hat{B}_0 + \hat{B}_1 \cdot Mean(Exposure)$$

The objective is to estimate the rate ratio (for exposure 0=no, 1=yes, or equivalently for a one unit increase in the exposure metric). That estimator is then:

$$rr = 1 + \hat{B}_1 / \hat{B}_0$$

The model estimated by the EPA method is:

$$Expected(rr | Exposure) = \hat{B}_1^* \cdot Mean(Exposure)$$

In the former, the variance in the estimation of the rate ratio is a function of the variance of the estimated slope and the variance in the estimated baseline hazard, represented by the estimated intercept. This variance is present in the estimation of the baseline hazard in the Steenland, et al. (2004) estimation of the rate ratios but is not present in the EPA adaptation

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 to the linear rate ratio model. The EPA approach permits no intercept (>0) for the
2 background exposure or any allowance for an effect of true non-zero exposures in the
3 internal control group (exposures less than 15 years).
4

5 In general, the use of categorical exposure ranges is not the optimal strategy for using
6 epidemiologic data. When continuous data are categorized and then used in dose response
7 modeling, it amounts to starting with a full range of exposures, collapsing that range into
8 somewhat arbitrary boundaries, and then deriving a continuous dose response model for an
9 even larger range of exposures.

10
11 Categorizing continuous variables results in a host of issues:

- 12 • Assumption that the risk within the category boundaries is constant
- 13 • It is not known whether a given categorization is representative of the data since there
14 are many ways of categorizing.
- 15 • Loss of power and precision by spending degrees of freedom on each category
- 16 • Misclassification at category boundaries (this can be minimized by choosing cutpoints
17 where relatively few observations are present)
- 18 • Categorizations can be manipulated to show the desired results

19
20 The Panel acknowledged that techniques such as the linear regression method
21 described by Rothman (1998) or Poisson regression may be the most appropriate techniques
22 when only grouped or categorized data are available for estimating the dose/response model.
23 However, the original NIOSH cohort data are available at the individual level and this
24 permits the use of models such as the Cox regression models employed by Steenland et al.
25 (2004) that utilize the full information in the individual observations. If categories of
26 exposure (as opposed to individual exposure estimates) must be used, the crude rates should
27 be computed for a large number of equally spaced exposure ranges and the Rothman and
28 Greenland (1998) model fitted to these multiple points.
29

30 31 3. Exclusion of high exposure groups

32
33 In conjunction with its recommendation to use the individual NIOSH cohort data to
34 model the relationship of cancer risk to exposures in the occupational range (see 2.B.1
35 above), the Panel recommends that the EPA analysts explore the use of the full NIOSH data
36 set to estimate the cancer slope coefficients that will in turn be used to extrapolate risk below
37 the established point of departure. The use of different data to estimate different dose
38 response curves should be avoided unless there is both strong biologic and statistical
39 justification for doing so. The Panel believed this justification was not made in the Agency's
40 draft report.
41

42 In the Draft Assessment, EPA analysts have faithfully adhered to the paradigm of
43 cancer dose response analysis usually used for animal data in analyzing the human
44 epidemiological data for this case. This is a useful step toward harmonizing the treatment of
45 animal and human-derived information in carcinogenic risk estimation. However, while

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 achieving operational consistency, the Agency's current analysis does not yet take into
2 account some important differences between animal and human carcinogenic dose response
3 data. These differences need to be factored in for designing a modern set of analytical
4 procedures for human data to achieve more comparable types of risk inferences and a better
5 analysis of uncertainties.

6
7 The most important differences in human vs. animal data that may require differences
8 in analytical approach are:

- 9
- 10 • Animal exposures are the result of intentional and consistent administration of the
11 test material at specific target levels, often reinforced with frequent empirical
12 measurements of differences between target exposures and actual delivered doses.
13 Human exposures, by contrast, are unintended, often variable over time, and at
14 best estimated from occasional measurements of exposures of the subjects
15 themselves or subjects considered to have similar exposures. Uncertainty in
16 exposures is thus nearly always much greater for human than for animal data.
17 Such uncertainties in human data lead to distortions in both central estimates and
18 uncertainties in potency estimates that require at least discussion and preferably
19 adjustment of ordinary dose response model fitting and "slope factor" estimation
20 procedures. Procedures for adjusting traditional regression analyses for such
21 effects are relatively well known in biostatistics under the general heading of
22 "errors in variables" models,* but have rarely been applied to occupational cancer
23 data in part because, unlike this case, exemplary quantitative analyses of likely
24 errors in exposure estimates have not often been available. There are some
25 examples of the use of errors in variables models in epidemiological studies of
26 other effects (Stayner et al. 2003; Richardson et al. 2004; Brown et al. 2004;
27 Choi, 2000; Carrothers and Evans, 2000; Kulathinal et al. 2002; Siebert et al.
28 2001). The current case, where very extensive efforts have been devoted to
29 development of exposure estimates and quantitative errors in exposure estimates
30 (Hornung et al. 1994), represents an invaluable opportunity to analyze and offset
31 the distortion in dose response estimates from this type of problem. The analysis
32 presented in Appendix C illustrates a relatively simple analytical approach to
33 gauging the extent of the modification in the low-dose cancer risk for male
34 lymphoid cancers that could be indicated for this case.
 - 35 • the subjects of human epidemiological studies may be subject to a variety of
36 selection biases, including the "healthy worker" effect, and the "healthy worker
37 survivor" effect. The former complicates comparisons with general population
38 mortality data, but the internal comparisons used for analyses of the Steenland et
39 al. (2004) avoid these. The "healthy worker survivor" effect (HWSE) is a known
phenomenon that produces established distortions in relationships between

* Ordinary regression models minimize the sum of the squares of the distance of the points to the regression line only in the "y" dimension (representing the dependent variable), "errors in variables" models minimize the weighted sum of squares distance as measured in terms of the uncertainties in both the dependent and independent variables.

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 measured risks and measures of cumulative exposure, as shorter term workers
2 suffer greater mortality than workers who work at exposure-producing jobs for
3 longer periods of time (Steenland et al., 1996; Kolstad and Olsen, 1999; Garshick
4 et al. 2004; Siebert et al. 2001; Steenland and Stayner 1991). Some Panel
5 members believed that the HWSE may be applicable for workers exposed to
6 Ethylene Oxide. Interestingly, in the light of the gender differences in the current
7 analysis, in at least one study the healthy worker effect was found to be greater
8 for women workers than for men (Lea et al. 1999). Adjustments for this effect
9 are at the cutting edge of current practice for the treatment of human
10 epidemiological data, but they are vital for achieving the best possible analysis of
11 those data. The authors of some of the leading studies documenting the healthy
12 worker survivor effect include authors involved in the Steenland et al. (2004)
13 ethylene oxide mortality study (e.g., Steenland et al., 1996; Stayner et al. 2003).
14 It might be useful for EPA to consult with Steenland and coworkers to judge
15 whether analytical adjustments for this effect are possible in this case. Even if the
16 data will not support the more complex analyses [and analyses of this sort are
17 notoriously complex (Robins, 1986; Arrighi and Hertz-Picciotto, 1996; Hertz-
18 Picciotto, personal communication) EPA could provide at least some discussion
19 of how large the distortions might be by citing previous cases such as the cancer
20 risks from diesel particles (Garshick et al. 2004) and the approach that California
21 risk assessors (and possibly others) have taken to risk analysis where the healthy
22 worker survivor effect is even more prominent than it may be in this case. (For
23 diesel particulates, the relative risk vs. cumulative dose curve even had a
24 negative, rather than a positive slope.)
25

26 Another source of the dose estimation problem that is more distinctive for this case is
27 the presence of a background of ethylene oxide exposure from endogenous generation.
28 Conceivably this could be substantial enough to limit the potency of ethylene oxide that
29 would be compatible with observations of "background" rates of lymphoid cancers in people
30 without occupational exposures. Should the EPA analysts accommodate this possibility by
31 adding estimates of exposure from this source (perhaps including variability and uncertainty)
32 to the estimates of occupational exposures for all the groups in the Steenland et al. (2004)
33 study? If so, how should such estimates be derived? In preliminary work, Hattis (see
34 Appendix B) attempted to estimate this effect using the model parameters and data from
35 Csanady et al. (2000). Generally, the exploratory work by Hattis (Appendix B) finds the
36 effect to be small enough (about 1.8 ppb occupational equivalent ethylene oxide exposure,
37 amounting to about 26 occupational equivalent ppm-days of cumulative exposure over a 60
38 year period) as not to be likely to appreciably distort the EPA analysis.
39

40 4. Cancer groupings

41
42 Although the analysis based on total LH cancers might have value as part of a complete
43 risk assessment, the rationale for this aggregate grouping needs to be better justified.
44 Certainly, a rational grouping of cancer types with a similar pathophysiology can lead to
45 improved power to detect significant effects of EtO exposure. By the same turn, grouping

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 cancers that affect a single organ system (e.g. blood) but with very different cancer etiology
2 could produce a spurious and therefore misleading result. The Panel therefore recommends
3 that data be analyzed by subtype of LH cancers with biological rationale for any groupings
4 that are formed.

5
6 Lymphohematopoietic (LH) cancers are diverse diseases with diverse, and often
7 multiple, etiologies, including exposure to ionizing radiation, viruses, and chemical
8 carcinogens, and genetic predisposition. The Draft Assessment argues that (a) all LH cancers
9 are a larger category, (b) there may be misclassification between LH categories, and (c) it
10 could be a relevant category because of the existence of multipotent stem cells. However, a
11 larger category that is made up of heterogeneous diagnoses is not desirable, one could
12 aggregate bladder and kidney cancers because they were both urinary system cancers, but
13 this would ignore their different etiologies. Even more marked differences exist between LH
14 categories, and even between leukemia cell types. The misclassification of disease mentioned
15 by the Draft Assessment (unspecified leukemias) would result in a slight loss of precision but
16 not necessarily a bias. Also, misclassification between lymphoid, myeloid and other cancers
17 is minimal. In addition, this issue exists within any organ system, e.g. there is some minimal
18 misclassification between kidney and bladder cancers but it is not a good reason to aggregate
19 the two cancers. While multipotent stem cells exist, research by Greaves (2004) suggests
20 that the initiating event for many haematopoietic cancers does not occur in the multipotent
21 stem cell. In addition, these cells are few in number and are likely to be well-protected
22 because of their critical function. Steenland et al's category of lymphoid tumors is more
23 consistent with modern lymphohaematopoietic classification techniques (WHO 2001) and
24 should be used as the preferred disease outcome.

25 26 5. Males Only

27
28 The Panel diverged in its views concerning the appropriateness of estimating the
29 population unit risk based only on the NIOSH data for males.

30
31 Several Panel members pointed out that a standard approach in cancer epidemiology
32 and risk analysis begins by conducting separate dose-response analyses on males and females
33 and combining the data only if the results are similar. This approach assumes the possibility
34 of known and unknown gender specific differences in the cancer etiology. Indeed, rates for
35 Non-Hodgkin's Lymphoma, Multiple Myeloma, and Leukemias are 25 to 60% higher in men
36 than in women (NCI, 2007). From a risk assessment perspective, it is protective against a
37 gap in our biological knowledge of an underlying mode of action that is truly gender
38 dependent. By the same turn, it is not a statistically conservative approach if in fact no
39 gender difference exists. In the case of no gender effect, a sex-specific analysis will have
40 reduced power to detect any common effect for women and men.

41
42 A second approach to dealing with the possibility of gender differences in response is
43 to include gender as a fixed effect in the statistical modeling of the data and determine
44 whether gender or its interaction with other predictors (e.g. gender x exposure) are
45 significant explanatory variables. If so, the combined model with the estimated gender

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 effects could be used directly or separate, gender-specific dose-response analysis would be
2 performed. If not, the gender effects could be dropped and the model re-estimated for the
3 combined male and female data.
4

5 Members of the Panel who argued for the second approach were concerned that there
6 appears to be no genetic or other physiological basis for the observed differences in the
7 trends observed for males and females (see overall SMRs). Women comprise 55% of the
8 NIOSH cohort and in general have lower average levels of cumulative exposures to EtO than
9 the males in the original cohort. From Steenland, et al. (2004), Table 4 the SMRs and
10 observed deaths for males and females in 5 categories of lagged (10 year) cumulative
11 exposure are:
12

13 Table 1: NIOSH Cohort. SMRs and observed lymphohematopoietic cancer deaths.

14 Source: Steenland et al. (2004)

Lagged (10) Cum Exp ppm-days	Male (n=7645)	Female (n=9885)
0 (prior to t-10)	1.15 (7)	0.31 (2)
1-1199	0.63 (5)	1.04 (13)
1200-3679	0.87 (5)	1.38 (10)
3680-13499	1.10 (7)	1.06 (9)
13500	1.46 (13)*	0.46 (3)

15 * 8 of 13 are NHL
16
17

18 Cox proportional hazards models with a random set of m=100 controls matched by
19 race, birth year and gender found no significant effect of the cumulative exposure level on
20 the all haematopoeitic cancer hazard for a combined analysis (p=0.20) or separately for
21 males (p=0.12) or females (p=0.34). Steenland et al. (2004) refitted the models to indicator
22 variables representing four quartiles of categorical exposure and again found no significant
23 relationship between the cumulative exposure category and the lymphohematopoietic cancer
24 hazard. Introducing time lags of 10, 15 and 20 years in cumulative exposure, Steenland et al.
25 (2004) re-estimated the proportional hazards models using both actual estimated exposure
26 values and the natural log transformation. For males only, the best fitting model (log
27 cumulative exposure, 15 year lag) achieved a marginal significance level (p=0.02). In the
28 broad class of models considered for females, the significance of the modeled relationship
29 between lymphohematopoietic cancer hazard and the various exposure metrics did not
30 approach significance under a nominal $\alpha = 0.05$ level.
31

32 Steenland, et al (2004) defend their model exploration steps against criticism of
33 possible “data dredging” (and thus consideration of multiple testing criteria) by pointing out
34 that prior work has shown latency (a lag in exposure measures) to be important in studies of
35 cancer for occupational exposures and that empirically the log of cumulative exposure has
36 provided a better fit to these types of time integrated data. To summarize, Steenland et al’s
37 work hints at a relationship between EtO exposure and all haematopoeitic cancer hazards, but

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 only for men and not for women. In a statistical sense, this evidence for an exposure
2 relationship in males is at best marginally significant and its estimated strength is influenced
3 by the chosen exposure metric—the best metric being the log of estimated cumulative
4 exposure (lagged to t-15 years). Similar sensitivity to the transformation of the exposure
5 metric is seen in the Cox regression results relating breast cancer hazard to EtO exposure.
6

7 Given these results, the EPA should carefully consider the scientific justification for a
8 “men only” model for its assessment of the risk of lymphohematopoietic cancer hazards.
9 There should be a strong scientific argument for excluding the female data. Presently, the
10 draft document identifies no basis for excluding the female data. In the data set, women on
11 average have lower average levels of estimated exposure to EtO (possibly more relevant to
12 the exposures of interest in the risk assessment). By the same turn, the results of the
13 extensive modeling effort suggest that the significance of the model fit is influenced by the
14 chosen exposure metric and the best fitting models are nonlinear with respect to exposure.
15 Panel members are not challenging the statistical analyses presented in the Steenland et al
16 (2004) paper. However, the Panel encourages the EPA to narrow its modeling efforts to
17 functional forms, exposure metrics, and disease outcomes that make sense from a biological
18 and risk assessment perspective. The process of model building should also include a
19 challenge to any model (e.g. log cumulative exposure, 15 year lag) which yields results that
20 differ substantially from a second model that only changes the scale of the exposure metric
21 (e.g. cumulative exposure, 15 year lag).
22

23 6. Preferred model justified, alternative analytical approaches.

24
25 As discussed in 2.b.1-2.b.4 above, the Panel recommended exploration of use of a
26 number of models, including non-linear models, to fit data within the observation range and
27 calculate a point of departure (POD). Preference for biologically-based models was
28 indicated.
29

30 7. Statistical issues

31
32 Pages 29-49 of the draft Evaluation outline the EPA’s proposed approach to estimation
33 of the Inhalation Unit Risk for EtO. In addition to the general issues of estimation and
34 model-based extrapolation described above, there are a number of statistical assumptions and
35 methods used in this approach that deserve mention.
36

37 Conditional on the cancer slope factor results from the weighted least squares
38 regression analysis, the life table (BEIR IV) approach to the determination of the LEC_{.01} is
39 programmed correctly.
40

41 The life table methodology that is the basis for the BEIR IV algorithm is designed to
42 estimate excess mortality and is not readily adapted to modeling excess risk for events
43 (incidence) that do not censor observation on the individual in population under study. The
44 methodology for substituting the mortality slope to an excess risk computation for HL cancer
45 incidence requires the assumption of a proportional rate of incidence/mortality across the

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 cancer types that are included in the grouped analysis. This is generally not a viable
2 assumption. The Panel therefore discourages the use of the BEIR IV algorithm for
3 extrapolation of the cancer mortality algorithm to estimation of excess cancer incidence.
4

5 Several Panel members commented on the use of the upper confidence limit for the
6 estimated slope coefficient as the basis for estimating an $LEC_{.01}$. The Panel encourages the
7 EPA to present unit risk estimates based on the range of $EC_{.01}$ values corresponding to the
8 lower 95% confidence limit, the point estimate, and the upper 95% confidence limit for the
9 estimated cancer slope coefficients from the final dose-response models.
10

11 **2.c. Age-dependent Adjustment**

12 **Is the incorporation of age-dependent adjustment factors (ADAF) in the lifetime cancer**
13 **unit risk estimate, in accordance with EPA's Supplemental Guidance (U.S. 2005b),**
14 **appropriate and transparently described?**
15
16

17
18 The Panel felt that the application of ADAF by the Agency was appropriate, but that
19 the description in the Draft Assessment was not adequate, particularly for those not familiar
20 with the EPA's Supplemental Guidance. A clear description of the ADAFs is important for
21 the Draft Assessment. For example, on page 57 line 15 the lifetime unit risk calculation
22 with ADAFs is presented. Unless the reader knows the binnings and associated uncertainty
23 factors, this would not be understandable to the average reader. There was also discussion of
24 the type of information that would be needed to address the issue of potential increased
25 sensitivity of children.
26

27 While the Panel recognized the role of the childhood exposure uncertainty factors in
28 the broader risk assessment process, it did not simply accept the defaults without first
29 attempting to establish the biological arguments for their application in the case of EtO. The
30 Draft Assessment states that because of the immaturity of detoxifying enzymes, a child's
31 susceptibility may be increased. This should, however, be extended to include the same
32 comment about DNA repair enzymes being immature, and the presence of more DNA
33 synthesis due to growth, and thus a further increased risk if exposure occurs during
34 development.
35

36 In general, the Panel concluded that the lack of data examining the impact of prenatal
37 and childhood exposure to ethylene oxide is a major limitation in the assessment of cancer
38 risk (Kim et al., 2006; Olshan et al., 2000; Anderson et al., 2000). Given this uncertainty, the
39 application of ADAFs in estimating cancer risks due to childhood exposure is warranted.
40



41 **2.d Models For Occupational And Environmental Exposures**

42 **Is the use of different models for estimation of potential carcinogenic risk to humans**
43 **from the higher exposure levels more typical of occupational exposures (versus the**
44
45

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 **lower exposure levels typical of environmental exposures) appropriate and**
2 **transparently described in Section 4.5?**
3

4 The use of different data to estimate different dose response curves should be avoided
5 unless there is both strong biologic and statistical justification for doing so. The Panel
6 believed this justification was not made in the Agency's draft report.
7

8 The Panel believes that fitting separate models for occupational and environmental
9 exposure levels, as proposed by EPA, requires some mechanistic justification. An alternative
10 is to provide fits based on two known distortions from the expected linear shape of dose
11 response relationships: the errors-in-variables issue as analyzed in Appendix C, and the
12 healthy worker survivor effect discussed elsewhere in this report. Such analyses are not
13 simple, but they do provide mechanistically justifiable ways to analyze the data without
14 either arbitrarily dividing the data in to different regions of exposure or adopting a
15 supralinear dose response form that does not have an obvious basis in plausible biological
16 mechanisms."
17

18
19 **2.e. Extrapolation from animal studies**
20

21 **Are the methodologies used to estimate the carcinogenic risk based on rodent data**
22 **appropriate and transparently described? Is the use of "ppm equivalence" adequate**
23 **for interspecies scaling of EtO exposures from the rodent data to humans?**
24

25 The ppm equivalence method is a reasonable method for interspecies scaling of EtO
26 exposures from rodent data to humans. If the use of animal data becomes more important
27 (i.e., the principal basis for the ethylene oxide unit risk value), more sophisticated approaches
28 such as PBPK modeling should be considered. The PBPK models that Filser's group (cite)
29 and Fennell and Brown (cite) have developed are appropriate. One Panel member conducted
30 a PBPK model some time ago and found that it gave very similar results to the ppm
31 equivalence approach, although this should be revisited [in the event that animal data assume
32 a greater role in the ethylene oxide unit risk].
33

34 All of the animal cancer data need to be presented as survival adjusted data.
35
36
37

1 **REFERENCES**

2 Akcakaya HR. 2002. Estimating the variance of survival rates and fecundities. *Animal*
3 *Conservation* 5:333-336.

4
5 Anderson LM, Diwan BA, Fear NT, Roman . Critical windows of exposure for children's
6 health:cancer in human epidemiological studies and neoplasms in experimental animal
7 models. *Environ Health Perspect* 2000; 108 Suppl 3:573-594.

8 Arrighi HM, Hertz-Picciotto I. 1996. Controlling the healthy worker survivor effect: an
9 example of arsenic exposure and respiratory cancer. *Occup Environ Med.* 53(7):455-462.

10 Baillargeon J. 2001. Characteristics of the healthy worker effect. *Occup Med.* 16(2):359-366.

11 Baillargeon J, Wilkinson GS. 1999. Characteristics of the healthy survivor effect among
12 male and female Hanford workers. *Am J Ind Med.* 35(4):343-347.

13
14 Brown SC, Schonbeck MF, McClure D, Baron AE, Navidi WC, Byers T, Rutenber AJ.
15 2004. Lung cancer and internal lung doses among plutonium workers at the Rocky Flats
16 Plant: a case-control study. *Am J Epidemiol.* 160(2):163-72.

17
18 Carrothers TJ, Evans JS. 2000. Assessing the impact of differential measurement error on
19 estimates of fine particle mortality. *J Air Waste Manag Assoc.* 2000 Jan;50(1):65-74.

20
21 Choi BC. 2000. A technique to re-assess epidemiologic evidence in light of the healthy
22 worker effect: the case of firefighting and heart disease. *J Occup Environ Med.* 42(10):1021-
23 34.

24 Csanady GA, Denk B, Putz C, Kreuzer PE, Kessler W, Baur C, Gargas ML, Filser JG. 2000.
25 A physiological toxicokinetic model for exogenous and endogenous ethylene and ethylene
26 oxide in rat, mouse, and human: Formation of 2-hydroxyethyl adducts with hemoglobin and
27 DNA. *Toxicol. Appl. Pharmacol.* 165:1-26.

28 Garshick E, Laden F, Hart JE, Rosner B, Smith TJ, Dockery DW, Speizer FE. 2004. Lung
29 cancer in railroad workers exposed to diesel exhaust. *Environ Health Perspect.*
30 112(15):1539-43.

31
32 Hattis D, Silver K, 1994. "Human interindividual variability--a major source of uncertainty
33 in assessing risks for non-cancer health effects." *Risk Analysis* 14:421-431.

34
35 Hong H-H L, Houle CD, Ton T-V, Sills RC (2007) *K-ras* mutations in lung tumors and
36 tumors of other organs are consistent with a common mechanism of ethylene oxide
37 tumorigenesis in the B6C3F1 mouse. *Toxicol Path* 35: 81-85.

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 Hornung R, Greife A, Stayner L, Steenland NK, Herrick RF, Elliott LJ, Ringenburg VL,
2 Morawetz J. 1994. Statistical model for prediction of retrospective exposure to ethylene
3 oxide in an occupational mortality study. *Am J Ind Med* 25: 825–836.

4
5 Houle CD, Ton T-V T, Clayton N, Huff J, Hong H-H, Sills RC (2006) Frequent *p53* and *H-*
6 *ras* mutations in benzene- and ethylene oxide-induced mammary gland carcinomas from
7 B6C3F1 mice. *Toxicol Path* 34: 752-762

8
9 Kim AS, Eastmond DA, Preston RJ. Childhood acute lymphocytic leukemia and
10 perspectives on risk assessment of early-life stage exposures. *Mutat Res* 2006;613:138-60.
11 Kolstad HA, Olsen J. 1999. Why do short term workers have high mortality? *Am J*
12 *Epidemiol.* 1999 Feb 15;149(4):347-52.

13 Kulathinal SB, Kuulasmaa K, Gasbarra D. 2002. Estimation of an errors-in-variables
14 regression model when the variances of the measurement errors vary between the
15 observations. *Stat Med.* 2002 Apr 30;21(8):1089-101.

16
17 Lea CS, Hertz-Picciotto I, Andersen A, Chang-Claude J, Olsen JH, Pesatori AC, Teppo L,
18 Westerholm P, Winter PD, Boffetta P. 1999. Gender differences in the healthy worker effect
19 among synthetic vitreous fiber workers. *Am J Epidemiol.* 150(10):1099-106.

20 Li CY, Sung FC. 1999. A review of the healthy worker effect in occupational epidemiology.
21 *Occup Med (Lond).* 49(4):225-229.

22
23 National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch,
24 Surveillance, Epidemiology, and End Results (SEER) Program, released April 2007, based
25 on the November 2006 submission.

26 SEER web pages where these data can be found as well as the suggested citation:

27 [http://seer.cancer.gov/faststats/sites.php?stat=Incidence&site=Non-](http://seer.cancer.gov/faststats/sites.php?stat=Incidence&site=Non-Hodgkin+Lymphoma&x=11&y=13)
28 [Hodgkin+Lymphoma&x=11&y=13](http://seer.cancer.gov/faststats/sites.php?stat=Incidence&site=Myeloma&x=18&y=14)

29 <http://seer.cancer.gov/faststats/sites.php?stat=Incidence&site=Myeloma&x=18&y=14>

30 <http://seer.cancer.gov/faststats/sites.php?stat=Incidence&site=Leukemia&x=15&y=14>

31
32 Olshan AF, Anderson L, Roman E, Fear N, Wolff M, Whyatt R, VuV, Diwan BA,
33 Potischman N. Workshop to identify critical windows of exposure for children's health:
34 cancer work group summary. *Environ Health Perspect* 2000; 108 Suppl 3:595-7.

35
36 Richardson D, Wing S, Steenland K, McKelvey W. 2004. Time-related aspects of the healthy
37 worker survivor effect. *Ann Epidemiol.* 14(9):633-9.

38 Robins J. 1986. A new approach to causal inference in mortality studies with a sustained
39 exposure period--application to control of the healthy worker survivor effect. *Mathemat*
40 *Modeling* 7:1393-1512.

41 Rothman, K.J. 1986. Modern Epidemiology. Little and Brown Co., Worcester, MA.

1

2 Rothman, K.J. and Greenland, S. 1998. Modern Epidemiology, Second Edition. Little and
3 Brown Co., Worcester, MA.

4

5 Siebert U, Rothenbacher D, Daniel U, Brenner H. 2001. Demonstration of the healthy worker
6 survivor effect in a cohort of workers in the construction industry. *Occup Environ Med.* 2001
7 Dec;58(12):774-9.

8

9 Stayner L, Steenland K, Dosemeci M, Hertz-Picciotto I. 2003. Attenuation of exposure-
10 response curves in occupational cohort studies at high exposure levels. *Scand J Work*
11 *Environ Health.* 29(4):317-24.

12

13 Stayner L, Steenland K, Greife A, Hornung R, Hayes RB, Nowlin S, Morawetz J,
14 Ringenborg V, Elliot L, Halperin W. 1993. Exposure-response analysis of cancer mortality in
15 a cohort of workers exposed to ethylene oxide. *Am J Epidemiol.* 138(10):787-798.

16

17 Steenland K, Deddens J, Salvan A, Stayner L. 1996. Negative bias in exposure-response
18 trends in occupational studies: modeling the healthy workers survivor effect. *Am J*
19 *Epidemiol.* 143(2):202-210.

20 Steenland K, Stayner L. 1991. The importance of employment status in occupational cohort
21 mortality studies. *Epidemiology.* 2(6):418-423.

Appendix A

Discussion of the Resurgent Controversy over Thresholds for Genetically Acting Agents Dale Hattis, Ph.D.

The roots of the historical controversy can be traced to a basic difference between different sets of disciplines in mental models of biological systems, and the ways that chemicals and other perturbing influences can cause effects. The disciplines of physiology, traditional toxicology and pharmacology tend to foster a view of biological systems as complex interacting webs of processes. These systems are seen as exquisitely designed so that perturbation of any one parameter automatically gives rise to countervailing adaptations that, if the perturbation is not too large, will keep the systems functioning within normal limits without serious or long lasting harm. This mental model leads directly to a general expectation that there should be thresholds in dose response; for any toxicant that acts by overwhelming some set of homeostatic processes there should be a dose below which the system can handle the perturbation without a meaningful adverse effect.

A different vision of some fundamental life processes arose from the ex-physicists who created the discipline of molecular biology in the decades after the end of World War II (e.g., Stent, 1963). This is the notion that there is a basic fragility in some functions that are central to life. When both somatic and germ cells divide, an enormous amount of information must be faithfully copied and distributed between the progeny cells. Mistakes can occur in this copying, and a change at even a single place in the DNA can give rise to important adverse (or, very rarely, beneficial) effects if by chance the mistake happens in just the wrong place in the DNA of the wrong cell. This leads to an intuition that even a single molecule of a DNA reactive chemical has a small but finite chance of doing lasting damage if it happens to react with the wrong place on DNA and if the DNA lesion is not repaired by the next time the DNA is copied.

In the 1970s and early 1980s it was recognized that basic bimolecular reaction kinetics require a fundamental linearity between the concentration of DNA reactants and relevant sites on DNA. However it was also recognized that there were many opportunities for at least high-dose nonlinearities both before and after DNA reaction in the sequence of events from intake of a DNA reactive agent (or a metabolic precursor) into the body to the ultimate manifestation of tumors (Hattis 1990).

In the 1970s some looked to pharmacokinetics as a potential source of threshold dose response relationships that might intervene between toxicant intake and the delivery of DNA reactive molecules to the nucleus of relevant cells. Figure 1 is an illustration similar to one that was published in *Science* (attributed to researchers at Dow Chemical) that attempted to make this pharmacokinetic-based threshold idea plausible. In the diagram, liquid

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.


1 (representing a continuous dosage of a toxicant) flows into a tank with two triangular holes.
2 The level of liquid rises in the tank until some begins to flow out of the lower of the two
3 holes (representing a high-affinity metabolic pathway producing a “safe” metabolite). A
4 further rise occurs until the amount of liquid flowing out of the tank equals the amount
5 flowing in. If the inflow is small enough that it can be completely balanced by flow out of
6 the lower hole, then the liquid will not rise to the level of the higher hole (representing the
7 lower affinity enzyme producing the dangerous metabolite). Thus the analogy predicts a
8 threshold of inflow into the tank, below which all of the metabolism is via the “safe” high
9 affinity pathway.

10 Unfortunately, this representation of the competition between higher and lower
11 affinity metabolic pathways is not compatible with conventional Michaelis-Menten enzyme
12 kinetics (Hattis, 1990; Slikker et al. 2004). Using the basic Michaelis/Menten equation, the
13 rate of the activating reaction (producing the dangerous metabolite, D) is:

1
2
3
4
5

Figure 1

**Argument for the Plausibility that Thresholds Might Arise From the Competition
Between Metabolic Pathways Producing Safe and Dangerous (DNA Reactive)
Metabolites**



This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

$$\frac{dD}{dt} = \frac{V_{\max}[C]}{K_m + [C]}$$

where [C] is the concentration of substrate (the form of the toxicant that is absorbed from the environment), Vmax is the maximum rate of the reaction that produces the dangerous metabolite, and Km (the Michaelis constant) is the substrate concentration at which the reaction proceeds at half of its maximum velocity (Vmax). Similarly the rate of the competitive detoxifying reaction (producing the safe metabolite, S) is:

$$\frac{dS}{dt} = \frac{V_{\max}'[C]}{K_m' + [C]}$$

The [C]'s in the denominator of both equations can be neglected at low doses when they become small relative to the Km's. At low doses we can therefore find the ratio of the substrate [C] that goes by the dangerous and safe metabolic pathways by simply dividing the two equations:

$$\frac{\text{rate of D production}}{\text{rate of S production}} = \frac{V_{\max}[C]/K_m}{V_{\max}'[C]/K_m'}$$

and because the numerator [C]'s now cancel, it can be seen that we are left with a ratio of four constants. This means that below the dose region where there is appreciable saturation of the enzymes producing either the safe or the dangerous metabolite, the fraction of the substrate taken by each pathway approaches a constant, independent of dose. There are no dose rate effects in this low dose region, there can be no thresholds, and indeed the system must operate linearly at the limit of low dosage, albeit with a different distribution of metabolism between "safe" and "dangerous" pathways than would be observed at higher doses. At the limit of high dose, the ratio of production of the dangerous to the safe metabolites is governed only by ratio of the two Vmax values; whereas at lower doses the Km's become progressively more involved. If the higher affinity (lower Km) pathway produces the dangerous metabolite, then the fraction of material metabolized by the dangerous pathway will be greater than at the highest saturating doses, resulting in a convex-upward dose response relationship for DNA damage (e.g. the pattern seen for vinyl chloride). On the other hand, if the safe pathway has the lower Km then the portion of the chemical processed by the safe pathway will be greater at lower doses than is seen at higher doses. In the abstract of a paper (Gehring et al 1978) describing a process model for carcinogenesis from electrophilic agents, Perry Gehring acknowledges that there should be an expectation

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 for some “albeit negligible” carcinogenic risk from genetically acting chemicals at low
2 doses.


3 It is well to emphasize that the basic Michaelis-Menten equation applied above is not
4 simply an empirical formula. It is well grounded in fundamental mechanistic considerations
5 of receptor association and dissociation kinetics with reasonably wide applicability (Hoel,
6 1985). The maximal velocity, V_{max} , arises because there are a limited number of enzyme
7 molecules available to catalyze the reaction, and each enzyme molecule is necessarily
8 constrained to operate at a finite rate in converting its substrate into its product. The fact that
9 the reaction proceeds linearly at low doses (with a rate constant of V_{max}/K_m) arises from
10 the fact that the reaction is limited by the rate of diffusion of the substrate molecules into the
11 active site of the enzyme—a rate that must be linear with substrate concentration at the limit
12 of low doses. In the light of this Figure 2 offers a more accurate molecular-scale vision of the
13 competition between enzyme-mediated activating and detoxifying processes. Each small
14 substrate molecule has a “random walk” through a cellular compartment as it rebounds from
15 collisions with other molecules. At the limit of low dosage, when there are few or no other
16 similar substrate molecules around, the substrate molecule must have a finite chance of
17 encountering the active site of each type of enzyme (or, similarly, a transport molecule taking
18 it to a different compartment). Therefore each type of enzyme or macromolecular transporter
19 must have finite opportunity to process the substrate molecule at the limit of low dosage.

20 The basic Michaelis-Menten equation form applies with equal force to active
21 transport processes (in which specialized molecules utilize energy to pump specific
22 molecules or ions into our out of cells), and to DNA repair processes. Thus the fundamental
23 expectation for low dose linearity applies similarly to these other components of the causal
24 chain between external exposure and the generation of somatic mutations that are
25 components of carcinogenesis. At the limit of low dose the Michaelis Menten
26 enzyme/transport reaction rates are limited by the rate of diffusion of substrate molecules
27 into the active sites of the enzymes/transport molecules; and those diffusion processes, given
28 a specific temperature, are linear functions of substrate concentrations.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

Figure 2

A Molecular Vision of the Low-Dose Competition for Substrate between Activating and Detoxifying Enzyme Molecules



1 With this as background, we can now examine the bases for some more recent claims
2 that thresholds should be expected at low doses for genetically acting agents. A convenient
3 starting point for this examination is a special issue of Mutation Research published in 2000
4 by participants at a conference on threshold mechanisms of carcinogenesis sponsored by the
5 European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC). Without
6 going through the threshold claims from each of the papers in this collection individually
7 (Kirshch-Volders et al. 2000; Schulte-Hermann et al. 2000; Muller and Kasper 2000;
8 Moustacchi 2000; Parry et al. 2000; Swenberg et al. 2000; Lowell 2000; Madle et al. 2000;
9 Henderson et al. 2000; Crebelli 2000; Kirkland and Muller 2000; Speit et al. 2000; Parry
10 2000), three main types of arguments stand out:

- 11 • Multiple targets. Some specific modes of genotoxicity are reported to depend
12 on multiple interactions between chemicals and target macromolecules (rather
13 than the single-DNA-reactant-molecule DNA adduct formation mechanism
14 discussed above). If the number of target interactions required to produce an
15 effect is large, the resulting low dose dose-response relationship can be
16 expected to be highly upward-turning, and well approximated by a threshold.
- 17 • Multiple barriers. A molecule of a chemically reactive agent must pass
18 multiple transport, potential detoxification, alternative targets for reaction
19 other than DNA, and DNA repair hurdles in order to cause a permanent
20 change in DNA sequence or chromosomal damage. The multiplicity of these
21 hurdles makes it unlikely that any single molecule could cause an actual
22 mutation along the pathway to carcinogenesis. If these multiple barriers do
23 not produce an “absolute threshold” they can at least be expected to lead to a
24 “pragmatic” or “practical” threshold below which exposure is of no real
25 biological consequence.
- 26 • Inducible detoxification, apoptosis, and/or DNA repair processes. One result
27 of exposure to a toxicant may be the induction of the levels of a variety of
28 cellular and genomic defense processes. If this induction is effective enough,
29 and occurs at low enough doses, it is possible that the prevention “good” that
30 results from avoidance or repair of mutagenic damage from background
31 processes may even be great enough to exceed the direct mutagenic harm
32 done by the toxicant itself. This gives rise to “hormetic” dose response
33 relationships in which the net mutagenesis and carcinogenesis is even reduced
34 by some range of exposures to the toxicant compared to background (zero
35 dose) levels.

36 *Modes of Genetic Action Requiring Multiple Interactions with Macromolecular* 37 *Target Molecules or Structures*

38 The first paper in the Mutation Research special issue (Kirsch-Volders et al. 2000)
39 gives a reasonable theoretical mathematical account of the dependence of the shape of the

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 dose response curve on the number of macromolecular targets that must be “hit” in order to
2 produce an effect. Essentially, if a single hit on DNA, an alpha or beta tubulin structure, or
3 topoisomerase is sufficient to cause an effect (assuming imperfect repair) then the
4 fundamental math calls for a single hit Poisson process:

$$5 \quad \text{Probability of Effect/Target} = 1 - e^{-m} \quad (1)$$

6 where m is the average number of “hits” per target. In cases where the number of hits per
7 target needed to cause an effect is larger than 1 (e.g. according to the authors, where the
8 target is the spindle drawing chromosomes to different progeny cells during mitosis, or the
9 nuclear membrane, by a mechanism that is not detailed in the paper), then the appropriate
10 Poisson term for n hits required per target is substituted:

$$11 \quad \text{Probability of Effect/Target} = 1 - e^{-m} \frac{m^n}{n!} \quad (2)$$

12 (where the notation n!, translated to English as “n factorial” means n X n-1 X All the way
13 down to 1.)

14
15
16 The larger the n, the more steeply upward-turning the resulting curve will be—increasingly
17 resembling, but not the same as a curve with a true threshold of zero probability of effect for
18 a finite dose.

19
20 Later on, Kirsch-Volders et al (2000). add:

21
22 “To be able to clearly assess a threshold, the spontaneous frequency of the analysed
23 endpoint should be very low, ideally equal to zero; indeed a too high spontaneous
24 background will lead to additive effects and a difficult estimation of small increases
25 at low dose level.”

26 This comment undermines considerably the generality of the earlier application of multi-hit
27 analysis to putative multi-target mutation/chromosomal damage mechanisms at very low
28 doses. Essentially it says that in order for the multi-hit formulas to apply at the limit of low
29 dosage, the genetically active agent must cause genetic changes by a mechanism that is
30 somehow distinct from all the processes that cause the appreciable background of genetic
31 changes from all other endogenous and exogenous agents, as well as the imperfections in
32 functioning of the apparatus of polymerases, spindle proteins etc. that maintain, copy and
33 transmit the genetic material.

34 The essential low-dose linearity of agents that act in concert with background
35 processes was discussed in some of the foundational papers that derived the methods for
36 inferring low dose cancer risks in the 1970s (e.g. Crump et al. 1976). This general
37 expectation can be illustrated with a simple example of a two-stage mutation process in

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 which there is a background of 1 arbitrary unit and an expectation for 1 additional induced
2 unit per 1 mg/kg continuous dose of a mutagenic agent (Table 2, adapted from Hattis and
3 Smith, 1986). It can be seen that at high doses, the dose response relationship between
4 excess tumors over background vs dose of the inducing agent appears almost perfectly
5 proportional to (dose)². This is because at high doses, far above the background rate of the
6 tumors, the agent predominantly acts by causing both mutations in the two-step process. As
7 the dose is reduced to regions where it causes mutations that are a small fraction of
8 background rates, the induced mutations predominantly cooperate with mutations that result
9 from the background processes—leading to an increment in tumors over background that
10 approaches linearity with dose of the added inducing mutagen.

11 One example of a process that may involve multiple targets is the action of spindle
12 poisons such as vinblastine and colcemid (Parry et al. 2000). Older observations by
13 Elhajouji et al (1995, 1997) are often cited as evidence of thresholds for agents that inhibit
14 spindle function. In vivo data are available in a recent report by Choudury et al. (2004).
15 However even in this case, it is worth compiling data on background rates and mechanisms
16 of spindle malfunction to assess the extent of potentially interacting background processes.

17

Table 2

Effect of Background Mutation Rates on the Carcinogenesis Dose-Response Curve at Low Doses, Assuming a Hypothetical Two-Stage Carcinogenic Process

Dose	Rate of 1 st Transition (1 extra unit per unit of dose)	Rate of 2 nd Transition (1 extra unit per unit of dose)	Relative No. of Tumors (background = 1) (product of two previous columns)	Induced Excess Over Background
1000	1001	1001	1,002,001	1,002,000
100	101	101	10,201	10,200
10	11	11	121	120
1	2	2	4	3
.1	1.1	1.1	1.21	0.21
0.01	1.01	1.01	1.0201	0.0201
0.001	1.001	1.001	1.002001	0.002001

Source: Adapted from Hattis and Smith, 1986.

1 A more questionable example of a postulated threshold process that seems
2 sometimes to be attributed to the multiple target type of theory is the inhibition of
3 topoisomerase* (Lynch et al. 2003; Bolt and Degen 2004). From the available description of
4 the mode of action of topoisomerases (see footnote) it is not completely clear that multiple
5 targets are involved in the action of topoisomerase inhibitors to enhance single- and double-
6 strand breaks at individual locations on DNA. A topoisomerase enzyme molecule apparently
7 acts by itself in stabilizing a double strand break at a specific place in DNA. An inhibited
8 enzyme molecule gives rise to a delay in religation with no mention of a need for
9 cooperativity either between inhibitor molecules or between inhibited enzyme molecules.
10 Nevertheless Lynch et al., after citing Kirsch-Volders et al (2000) and other papers in the
11 same special issue of Mutation Research proceed to assume that because the interaction of
12 inhibitor is not directly with DNA, a threshold theory for the topoisomerase inhibitor mode
13 of action is biologically justified. They then go on to offer as experimental evidence, a
14 particular kind of plot of dose response results for in vitro induction of micronuclei by three
15 different topoisomerase inhibitors (Figures 3-5, but not Figure 6). In the first three of these
16 plots the log of the % micronuclei is plotted vs the log of the concentration of the
17 topoisomerase inhibitor in the culture

* In the last two decades an important role has become apparent for topoisomerase II in normal DNA replication. This enzyme gets its name from its function to change the topology of DNA during replication, transcription, and repair. It binds covalently to DNA in such a way as to produce a temporary double-strand break, allowing another DNA strand to pass through it. After this, normally the breaks in the two strands are rejoined (religated). However some compounds (DNA topoisomerase inhibitors) can stabilize the usually transient state of the complex with the double strand break unrepaired, and inhibit religation. This leads to chromosome breakage and rejoining events that in rare cases splice together inappropriate portions of different genes leading to uncontrolled cellular growth promotion signals. Just such gene fusions are responsible for a key step in the development of several types of Acute Lymphocytic and Acute Myeloid Leukemia in children (Lightfoot and Roman 2004). By examining blood spots made at birth in children who later developed leukemia, it has been found that these events often happen before during fetal life; to be followed by one or more subsequent steps in leukemia development after birth (Gale et al. 1997). Epidemiological studies indicate that cases of adult leukemias occur at increased frequency after chemotherapy with topoisomerase II inhibitors for other cancers (Greaves, 1999; Le Deley et al. 2007) compared to patients treated with other types of chemotherapy. Topoisomerases inhibitors are also used deliberately in the control of HIV, but activity of this type has also been reported from a metabolite of the headache remedy acetaminophen (Bender et al. 2004) and in a wide variety of foods and herbal medicines (Lightfoot and Roman, 2004). So far, there is limited evidence that maternal dietary consumption of specific DNA topoisomerase II inhibitors increases the risk of gene fusion related leukemias (Spector et al. 2005; Alexander et al. 2001; Ross 1998).


1

Figure 3

2

Log-Log Plot From Lynch et al. (2003) Offered in Support of a Threshold in the
3 Dose Response Relationship for Induction of Micronuclei in L5178Y Mouse Lymphoma
4 Cells by the Topoisomerase Inhibitor Etoposide*

4



5

6

7

8

9

10

11

12

13

* Source: Lynch et al. 2003. The different colored points represent different assays. The caption to this graph is “Broken stick model. The breakpoint was identified at $\ln(\text{conc.}) = -6.049$ or $0.00236 \mu\text{g/ml}$ on the original concentration scale with $\ln(\%MN) = -0.364$ fitted before the breakpoint and $\ln(\%MN) = -5.234 + .94 \times \ln(\text{conc})$ fitted afterwards. The goodness of fit (R^2) was 93.4%.”

1


Figure 4

2

Log-Log Plot From Lynch et al. (2003) Offered in Support of a Threshold in the
Dose Response Relationship for Induction of Micronuclei in L5178Y Mouse Lymphoma
Cells by the Topoisomerase Inhibitor Doxorubicin*

3

4



5

6

7

8

9

10


* Source: Lynch et al. 2003. The different colored points represent different assays. The caption to this graph is “Broken stick model. The breakpoint was identified at $\ln(\text{conc.}) = -6.495$ or $0.00151 \mu\text{g/ml}$ on the original concentration scale with $\ln(\%MN) = -0.135$ before the breakpoint and $\ln(\%MN) = -5.674 + 0.979 \times \ln(\text{conc})$ fitted afterwards. The goodness of fit (R^2) was 89.2%.”

1

Figure 5

2

Log-Log Plot From Lynch et al. (2003) Offered in Support of a Threshold in the Dose Response Relationship for Induction of Micronuclei in L5178Y Mouse Lymphoma Cells by the Topoisomerase Inhibitor Genestein*

3
4

5

6

7

8

9

10

* Source: Lynch et al. 2003. The different colored points represent different assays. The caption to this graph is “Broken stick model. The breakpoint was identified at $\ln(\text{conc.}) = 0$ or $1 \mu\text{g/ml}$ on the original concentration scale with $\ln(\%MN) = -0.817$ before the breakpoint and $\ln(\%MN) = -1.117 + 1.508 \times \ln(\text{conc.})$ fitted afterwards. The goodness of fit (R^2) was 88%.”


1

Figure 6

2

3 **Linear %MN vs Linear(concentration) Plot From Lynch et al. (2003) Offered in**
4 **Support of a Threshold in the Dose Response Relationship for Induction of Micronuclei**
in L5178Y Mouse Lymphoma Cells by the Topoisomerase Inhibitor Ciprofloxacin *

4



5

6

7

8

9

10

11

12

* Source: Lynch et al. 2003. The different colored points represent different assays. The caption to this graph is “Broken stick model. The breakpoint was identified at conc. =40 $\mu\text{g/ml}$ with % micronuclei = 0.636 fitted before the breakpoint and % MN = $0.392 + 0.016 X$ conc. Fitted after the breakpoint. The goodness of fit (R^2) was 77.1%.”

1


2 The log log plots of Figures 3-5 are an example of how disciplinary perspectives can
3 shape the presentation and interpretation of evidence. From a toxicological perspective,
4 there are two realms of concern – the realm of homeostasis and the realm in which
5 homeostasis has broken down. Then using a logarithmic plot for the x axis seems
6 appropriate since the logarithm of concentration makes available a great space on the graph
7 for the very low doses that would be relevant if homeostatic effects were dominant.
8 However the data in this low putative homeostatic realm are almost always completely
9 uninformative. From a molecular biological perspective as well as an experimental
10 biological perspective, the putative homeostatic region is one for which the data are
11 consistent with a linear extrapolation to zero or to a fixed background as can be seen quite
12 clearly in Figure 6 (despite the misleading line and commentary).

13 Whether or not thresholds are assumed to exist, log log plots such as 3-5 can serve to
14 illustrate the state of the experimental data in that region. However, in general, because a log
15 log plot expands (potentially indefinitely) the curve near zero, even a linear no-threshold
16 function with a background level unaffected by the toxicant will exhibit a “broken-stick”
17 appearance (Figure 7). And whenever there is lack of precision in measurements (giving rise
18 to an implicit background and obscuring the fine curvature barely discernable in Figure 6),
19 the cosmetic effect that gives the appearance of two lines will be enhanced. For that reason
20 log log plots have no force as evidence for the existence of thresholds. Thus, contrary to the
21 suggestions by Wadell (2006; 2003) for tumor data more generally, anyone starting from a
22 molecular or experimental perspective is likely to regard such plots as distracting from a
23 natural linear extrapolation. [See also the published critique of Haseman (2003).] In our
24 view such plots may be used (if presented carefully) to characterize data availability in a low
25 dose region; but any presentation as evidence for threshold behavior is fundamentally
26 misleading.

1

Figure 7

Plot of Log(y) vs Log(x) for the Simple
Linear Relationship, $y = .392 + .016x$
With Regression Line Fit to Last 4 Points



2

3

4

1 *Arguments for Absolute Thresholds or “Practical Thresholds” from the Presence of*
2 *Multiple Transport, Detoxification, and Repair Processes*

3
4 The “multiple barriers” argument appears to be mostly a rhetorical device since its
5 mathematical implications reinforce linearity. By reciting the series of opportunities that a
6 molecule of a DNA-reactive agent has to go astray rather than react with DNA and then have
7 the adduct cause a mutation in a gene that matters in a cell that matters for carcinogenesis, a
8 speaker can make it appear very unlikely that such a chain of events could occur (Parry et al.
9 2000). And indeed, from the standpoint of a single molecule, the probability is necessarily
10 very small. However each physical barrier has some probability of being surmounted by
11 each molecule; each alternate reaction opportunity or detoxification enzyme will divert a
12 finite fraction of the molecules, each DNA repair process will repair the molecules/adducts at
13 a finite rate and therefore a finite fraction of the DNA lesions will persist to the time of the
14 next passage of the polymerase enzyme responsible for copying the DNA. Similarly not all
15 cells with damaged DNA will be removed by apoptosis, and cell cycle checkpoint functions
16 will not perfectly prevent the copying of damaged DNA. If there is a finite rate of DNA
17 lesion generation and a finite rate of DNA repair or removal by apoptosis, then there must be
18 a finite rate of mutation that, at the limit of low dosage where saturation effects are
19 negligible, must be a linear function of the number of DNA reactive molecules (or their
20 precursors) that enter the system. Moreover once an initial tumor cell is generated there must
21 be a finite probability that it will escape repression by its normal neighbors through gap
22 junction communication and by other immune-based defense processes. The presumption of
23 some of the discussion in the Mutation Research special issue (Herman et al. 2000) seems to
24 be that at low doses some or many of these processes can be assumed to be perfect; but this
25 is just not possible. The dose response relationship for the combined process is a simple
26 multiplicative combination of the component processes. If all of these are linear at low
27 doses, then the combined dose response relationship must also be linear at low doses.

28 A final refuge of this set of arguments is to distinguish between an “absolute”
29 threshold (a true zero response at a finite dose rate)* and a “pragmatic” or “practical”
30 threshold. Lowell (2000) argues:

31 “A ‘pragmatic’ threshold can be considered as a concentration below which any
32 effect is considered biologically unimportant (Figure 2)** (Lutz, 1998). This term is
33 used in a somewhat similar way to how ECETOC defines a biological threshold
34 except that it implies that there may be effects occurring because of treatment or
35 exposure but these are considered below what might be considered biologically

* Lowell (2000) quotes a somewhat different definition of “absolute” threshold attributed to ECETOC: “...a concentration below which a cell would not ‘notice’ the presence of the chemical. In other words, the chemical is present but does not interact with the cellular target.” The precise identification of such a threshold, if it exists is difficult.

** The figure referred to is not reproduced here. It shows an upward turning dose response curve beginning at the origin (zero response at zero dose) but a region of response shaded and labeled as “Biologically unimportant”. The point where the continuously increasing dose response curve emerges from this “unimportant” shaded region is labeled as the “Practical Threshold”.

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

important. An example might be increases that did not exceed the range of responses seen in negative control material in a well-conducted series of experiments. Such a threshold may be defined, in part, with the help of statistical tests. The distinction between the various classifications of thresholds can initiate a philosophical discussion but is not relevant to regulatory risk assessment.”

It appears, therefore, that this line of argument reverts to treating an effect that may be present but which cannot be clearly demonstrated as above “the range of responses seen in negative control material” (with some undefined sample size and sensitivity/detection noise) as if it weren’t there. It seems to us that risk assessment methods have been created precisely to make fair assessments of the likely magnitude of effects that cannot be directly measured but are still potentially substantial enough that decision-makers and the public may reasonably care about reducing them. Or, put another way, “practical” for a biologist to detect, may not mean the same as of “practical” concern because someone might get hurt. Our view is that terms such as “practical threshold” are inherently evasive and do a disservice to transparent public analysis and discussion of likely underlying realities.

Arguments for Thresholds or Hormetic Dose Response Relationships from Possible Inducible Detoxification or DNA Repair Processes

In contrast to some of the arguments reviewed above, this category of mechanisms does have some potential to produce changes to the low dose linear expectation under some circumstances. Up to this point we have discussed the several processes producing high dose nonlinearities in dose response relationships as if their levels were static—fixed at some baseline level of activity/efficiency in promoting or reducing damage to DNA or subsequent steps in the carcinogenic process. In fact, however, it is not unlikely that the levels of the enzymes that mediate these processes are themselves regulated by feedback mechanisms that respond to influences from the external and internal environment, as do many other components of biological systems (Schulkin, 2003). It is certainly possible, in theory, that under some circumstances the induction of detoxifying or DNA repair enzymes (e.g. from radiation--Schmerold and Wiestler 1986; Chan et al. 1992) could have the side-effect of preventing or repairing enough “background” damage as to outweigh the primary damage done by the inducing toxicant over some range of dosage. Whether such possible offsetting effects could extend all the way down to the limit of low dosage depends on the fundamental dose response relationships underlying the induction process(es) and the levels and types of “background” damage of the that are available to be prevented.

Specifying the requirements for this helps illuminate the special nature of the conditions that would be needed to produce a net biological benefit from a particular type of exposure to a genetically active agent:

- “Background damage” (e.g. from the DNA damaging free radicals produced as a byproduct of metabolism, other endogenous DNA reactive agents such as ethylene oxide and possibly formaldehyde, and other exogenous DNA reactive

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

agents) must occur at sufficient rates that offsetting prevention benefits could occur,

- The usual “baseline” state of expression of the detoxification, DNA repair, apoptosis, or cell cycle check point mediators needs to be sub-optimal. Normally, one would expect that if it were net beneficial to have higher standing levels of a particular enzyme, then that would have been of selective advantage during evolution. Consequently people’s normal constitutive should have been adjusted to at least approximate optimality by natural selection. However, the types and levels of present-day exposures to mutagenic agents could conceivably be different enough from those present during the recent evolution of modern humans that prevailing constitutive levels of defensive enzymes are not perfectly tuned to current exposures. (For example cancer rates in wealthier industrialized countries tend to be very substantially higher than in poorer, less-developed countries. (Harris et al.1985)) In evaluating such possibilities, it is important to bear in mind that both detoxification enzymes and DNA repair enzymes can have adverse biological side-effects themselves. For example the same P450 “detoxification” enzyme that is induced by ethyl alcohol (Daiker et al. 2000; Feierman et al. 2003; Sato 1993) also is involved in the transformation of vinyl chloride to the activated form that reacts with DNA to induce the characteristic liver cancers produced by that compound. Epidemiologic data now exist indicating that high consumers of alcohol are much more susceptible to the carcinogenic effects of vinyl chloride (Mastrangelo et. al 2004). P450s also affect estrogen metabolism including some to genetically active agents. DNA excision repair enzymes, which repair DNA by cutting out small sections of DNA that has been damaged, also do damage themselves by making cuts at some finite rate in sections of DNA that do not contain pre-existing damage (Branum et al. 2001). Thus it is likely to be beneficial, biologically, to induce these enzymes above their baseline levels only when there is sufficient damage in a particular cell that the biological “costs” of the excision repair enzyme itself are outweighed by the need to repair an unusual amount of damage by a relatively rare exposure episode.

- The dose-response relationship(s) for induction of the detoxification and/or repair enzymes has to be steep enough, and the induction long lasting enough, that the prevention benefits are sufficient to offset the primary damage done by the inducing agent.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

Appendix B

Illustration of a Simple Approach for Approximately Assessing the Effect of Measurement/Estimation Uncertainties for Individual Worker Exposures on Estimates of Dose Response Slopes*

Dale Hattis, Ph.D.

There are several steps in this analysis:

- A. Use the cross-validation results for the Hornung et al. (1994) exposure estimation model to derive a preliminary quantitative estimate of the minimal likely measurement/estimation errors in the exposure levels used for calculating cumulative exposure for individual workers.
- B. Derive an analytical expression for the observed distribution of individual male worker exposures in the reference group (that is, the non-lymphopietic cancer cases) in the Steenland et al. (2004) study.
- C. Remove the (assumed lognormal) variance attributable to random measurement/estimation errors from the lognormal variance of the observed worker exposures to derive an estimate of the lognormal variance of the real worker exposures.
- D. Derive adjusted estimates of the likely real mean cumulative exposures of workers in each of the four categorical dose groups.
- E. Redo the regression analyses of relative risk vs cumulative dose using the adjusted estimates of mean cumulative dose in each exposure group; assess the effects on the results of assuming larger estimates of measurement error than those directly derived from the Hornung et al. (1994) cross-validation analysis.

- **Implications of the Cross-Validation Results for the Hornung et al. (1994) Exposure Estimation Model**

Hornung et al. (1994), as part of the exemplary exposure assessment effort that led to the Steenland et al. (2004) study, gathered a total of 251 annual arithmetic means of measured ethylene oxide exposure levels in specific sets of job titles at 18 sterilization facilities based on 2700 individual full-shift charcoal tube samples. Before developing their

* An updated version of this case study will appear in a white paper on uncertainty in cancer risk assessment that is in process under separate EPA funding.

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 exposure model, the data from 6 randomly selected plants (including 46 annual arithmetic
2 means based on 350 individual charcoal tube samples) were set aside for later “validation”
3 analysis of model performance. The model predicted individual annual exposures based on
4 job/exposure category, product type, age of product, calendar year, rear exhaust, aeration
5 procedure, and sterilizer volume. Table 1 summarizes the performance of the eventual
6 exposure model—juxtaposing these 46 values with the eventual model predictions.
7

8 **Table 1**

9 **Hornung et al. (1994) Comparison of Model-Predicted Annual Average 8-Hour**
10 **Average Time-Weighted Average Exposure Levels with 46 Observations Not Included**
11 **in the Data Used to Develop the Model**

	Measured Level (ppm)	Model 2 "Prediction" (ppm)	Measured/ Model ratio
Gmean	2.22	1.5	1.48
Geom. Std. Dev.	3.8	5.09	.
Arith mean	4.62	3.5	1.32
Standard dev	5.76	3.79	.
Range	0.1-32.0	0.05-15.7	.

12 Bias = average of all 46 d_i 's where d_i = prediction – measurement = 1.13 ppm

13 Precision = standard deviation of all d_i = 3.66 ppm

14
15 Overall the precision of the model predictions was superior (less) than the predictions of 11
16 different industrial hygienists with access to the same information, considered individually or
17 collectively.

18 For purposes of this analysis it is desirable to separate the contribution of the
19 indicated “bias” (apparent systematic underprediction of exposures relative to the measured
20 exposures) to the random error represented by the “precision” measure of deviation. The
21 minimum estimate of the contribution of the “bias” to the variance (square of the standard
22 deviation) represented by the “precision” observation is
23

24 Prediction variance = Precision² – Bias² = 13.4 – 1.3 = 12.1 ppm²
25

26 In terms of an arithmetic standard deviation, the adjusted “precision” estimate is therefore
27 (12.1)^{0.5} = 3.48 ppm. Dividing by the arithmetic mean of 4.62 ppm this yields a precision
28 coefficient of variation of about 0.75.
29

30 It is clear from the relatively large ratio of the arithmetic standard deviations to the
31 means of both the measured and model predicted values that the distributions will be better
32 described by lognormal than arithmetic distributional statistics. (This is nearly always the
33 case for exposure distributions.) Fortunately one can use a standard formula (Aitchison and

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 Brown, 1957) to convert the “precision” coefficient of variation to an estimate of the
2 geometric standard deviation (the antilog of the standard deviation of the log-transformed
3 exposure values). Where CV is the coefficient of variation, an estimate of the geometric
4 standard deviation is:
5

$$6 \quad \text{Geometric Standard Deviation} = e^{\{\ln[CV^2+1]\}^{0.5}}$$

7
8 Applying this formula to the precision CV derived above yields a geometric standard
9 deviation of 1.95 (about 2)—meaning that the random error in the exposure estimates is such
10 that about 2/3 of the estimated values are expected to be within 2-fold of the actual values;
11 and 95% of the estimates are expected to be within 4-fold of the true exposures.

12 In fact, however, there is reason to expect that the actual uncertainty may be larger
13 than this. All of the exposure measurements used to derive and test the model were from the
14 mid 1970s and later, whereas some of the exposures that were estimated appear to go back to
15 the first regular use of ethylene oxide for sterilization in 1938 (Stayner et al. 1973). In the
16 use of their exposure model, Hornung et al. assumed that exposures prior to 1978 were equal
17 to the values that would apply to 1978. This creates some additional uncertainty in the
18 exposure analysis that is not captured in the analysis of precision of exposure estimates from
19 the 1970s and 1980s. Therefore the analysis below will include a hypothetical case assuming
20 a much larger random error (3 times the estimated variance, corresponding to a geometric
21 standard deviation of about 3.2) than that directly derived from the estimated imprecision in
22 1970s-1980s exposures.

23
24 • **Estimating the Cumulative Exposure Distribution for the Reference Group (Non-
25 Lymphoid Cancer Cases)**

26 The main inputs for estimating the 15-year lagged exposure distribution for the
27 reference group were the boundary lines for the exposure categories and the estimated
28 numbers of workers in each category of accumulated exposure (Table 2). An initial
29 probability plot of based only on the estimated numbers of workers with finite exposures in
30 the different groups (Figure 1) led to the conclusion that the data (represented by the points)
31 are reasonably described by a lognormal distribution (the fitted line) with a geometric mean
32 of about $10^{0.336} = 2320$ ppm-days and a geometric standard deviation of about $10^{1.22} = 16.6$.

1
2
3
4


Table 2
Inputs for the Estimation of the Distribution of Exposures in Referent Workers (Non-Lymphohematopoietic Cancer Cases)

Exposure Group	median exp (ppm-days)	mean exp (ppm-days)	RR
0 (lagged out)	0	0	1
<1200 ppm-days	360	442	1.23
1200-3679	2093	2191	2.52
3680-13499	6230	7105	3.13
≥13500	43212	60269	3.42

5
6
7
8
9

Figure 1
Initial Lognormal Probability Plot of the Exposure Distribution for Referent Workers Based on the Estimated Numbers within Each Group

Lognormal Plot of the Implied Distribution of 15-Year Lagged Exposures for the Male Non-Cases in the Steenland et al (2004) Study



10
11
12

A more extensive optimization analysis using the additional information on the within-group means and medians for the exposure groups from Table 2 led to an adjustment of the basic parameters for the lognormal distribution (geometric mean = 2910 ppm and geometric standard deviation = 9.86) and a conclusion that the exposure estimates were

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

likely to be truncated at about 337,500 ppm-days (corresponding to 45 years of 250 day/year 8 hr/day occupational exposure at an average of 30 ppm, which would otherwise correspond to about the 98th percentile of a full lognormal distribution). This truncation point was chosen to avoid having key model parameters such as the mean of the highest exposure group being importantly dependent on cumulative exposures that are not likely to be present in the actual data. The resulting fit to the referent within-group mean and median cumulative exposure information is shown in Table 3.

Table 3

Fit of the Derived Referent Exposure Distribution to the Within-Group Mean and Median Exposure Data

Exposure Group (ppm-days)	Observations		Lognormal Model "Predictions" ^a		Ratio: Model "Predictions"/Observations	
	median exp (ppm-days)	mean exp (ppm-days)	median exp (ppm-days)	mean exp (ppm-days)	median exp (ppm-days)	mean exp (ppm-days)
0 (lagged out)	0	0				
<1200	360	442	342	426	0.949	0.964
1200-3679	2093	2191	2121	2226	1.013	1.016
3680-13499	6230	7105	6805	7376	1.092	1.038
≥13500 ^a	43212	60269	36277 ^a	62371 ^a	0.840 ^a	1.035 ^a

^aWith truncation of the ≥13500 category at 337,500 ppm-days.

Overall, although the fit to the truncated lognormal distribution is not as close as might be hoped (particularly for the within-group median for the largest exposure group, the predictions for the key within-group means are not unacceptable, with no "prediction" departing from the reported observed mean by more than 4%.

- **Remove the (Assumed Lognormal) Variance Attributable to Random Measurement/Estimation Errors from the Observed Lognormal Variance to Estimate the Lognormal Variance of the Real Worker Exposures**

In the special case where both the distributions of the true worker exposures and the distribution of measurement/estimation errors are lognormal, then the lognormal variance of the observed distribution is just the sum of the real exposure variance and the error variance. This simplifying assumption allows us to estimate the lognormal variance of the real underlying worker exposures as:

$$\text{Real lognormal variance [the square of the real log(geometric standard deviation)] = Observed lognormal variance - lognormal variance from measurement/estimation error} \\ = [\log(9.86)]^2 - [\log(1.95)]^2 = 0.903$$

8-30-07 DRAFT
Science Advisory Board (SAB) Ethylene Oxide Review Panel Draft Advisory Report
-- Do Not Cite or Quote --

This Draft is made available for review and approval by the chartered Science Advisory Board.
This Draft does not represent EPA policy.

1 This lognormal variance implies a geometric standard deviation of about 8.92—
 2 slightly reduced from the geometric standard deviation of the observations of 9.86.
 3 Similarly, if we choose to assume that the measurement/estimation variance is as much as
 4 three times that derived from the Hornung et al. validation comparison the reduced estimate
 5 of the real variability in exposures corresponds to a geometric standard deviation of about
 6 7.18.

7 Similar variance subtraction techniques have been used previously to quantify likely
 8 underlying real variability in a wide variety of parameters including survival and fecundity
 9 rates in ecological analyses and coal miner breathing rates (Akcakaya 2002; Hattis and Silver
 10 1994). For the more general case where the distributional forms of the real variation and
 11 measurement variation one needs “errors in variables” regression models (Stayner et al.
 12 2003; Richardson et al. 2004; Brown et al. 2004; Choi, 2000; Carrothers and Evans, 2000;
 13 Kulathinal et al. 2002; Siebert et al. 2001 or more complex “deconvolution” procedures that
 14 are not yet in widespread use.

15
 16 • **Derivation of Adjusted Estimates of the Real Distribution of Cumulative Exposures**
 17 **in Each of the Four Categorical Dose Groups**

18 Using the adjusted estimates of the geometric standard deviation and the same
 19 geometric mean and upper percentile truncation point derived earlier, it is straightforward to
 20 calculate a large number of percentiles of the indicated lognormal distributions and the mean
 21 values for exposures in each of the worker groups. The results in Table 3 are derived from
 22 dividing the original and error-variance corrected lognormal distributions into 3700 equal
 23 parts corresponding to the number of referent workers at a 100:1 ratio to cases (the exact
 24 number is not critical).

25 **Table 3**
 26 **Changes in Estimates of Mean Cumulative Exposures in Previously Defined Groups**
 27 **Using the Simple “Regression to the Mean” Effect**

Exposure group (ppm-days for original observations)	Original Observations	Lognormal Fit to Original Observations	Error = GSD 1.95	Error = GSD 3.2
<1200	442	426	457	533
1200-3679	2191	2226	2247	2296
3680-13499	7105	7376	7060	6433
≥13500-337500	60269	62371	53629	38942

28
 29 It can be seen in Table 3 that the narrowing of the distributions by subtraction of
 30 estimation error causes a reversion toward the mid point of the exposure distribution. The
 31 estimates of the mean cumulative exposures for the lower two groups are raised; and the
 32 estimated means for the higher two groups are lowered, with the greatest effects seen on the
 33 group with the largest exposures.

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

In addition to the regression to the mean effect shown in Table 3, there is an additional effect that results from what is classically known as “classification error”. The error in estimating individual workers’ exposures causes some estimated exposures to be ‘scrambled’—that is, misclassified from their real exposure ranges to adjacent ranges. To model this, ten replicate Monte Carlo simulations were done of 3700 trials each for both assumed error level. On each trial, a random draw was made from the estimated underlying lognormal distribution of real exposures (after subtracting the variance attributed to measurement error) and then a random perturbation was added back corresponding to the lognormal distribution of measurement errors. The final two columns of Table 4 show the effects of this on the true mean exposures within each group for workers classified into exposure groups using their “observed”/estimated exposure levels. The calculation also took into account the censoring of both the “real” and estimated exposures at 337,500 ppm-days. Comparing Table 4 with Table 3, it can be seen that that undoing the effects of this scrambling misclassification leads to a much larger set of changes in the estimated real exposures within each of the groups of workers classified by observed exposures.

Table 4
Changes in Estimates of Mean Cumulative Exposures (ppm-days) in Previously Defined Groups after Including the Scrambling of Individual Exposures among Exposure Groups

Exposure group (ppm-days for original observations)	Original Observations	Lognormal Fit to Original Observations	Error = GSD 1.95 After Scramble	Error = GSD 3.2 After Scramble
<1200	442	426	593	1264
1200-3679	2191	2226	2822	3836
3680-13499	7105	7376	8416	8415
≥13500-337500	60269	62371	51440	29290

These shifts have predictable effects on the estimates of the linear cancer potencies (Tables 5-6), using the same estimation methods (based on the same spreadsheet formulas) as were used by the EPA analysts. In the case of the 3 point calculation (Table 5), the overall effects are modest—slope factor estimates even decrease somewhat in the calculations with the scramble effect because of the increased estimated real mean exposure for workers with in the observed 3,680—13,499 ppm-day group. The full implications of the different amounts of estimation error are more apparent for the full analysis of all four points (Table 6). It can be seen that in this case the effect of the GSD 1.95 estimate of measurement error is to increase the slope factor by about 25%; whereas the effect of the larger GSD 3.2 assumption for estimation error is to slightly more than double the estimate of low dose risk. In the latter case, the ratio of the low-dose risks projected using the 3- vs the 4-point analysis is reduced to about 3-fold, compared with about 7.5-fold using the group means of the original observations. Thus, errors-in-variables distortion of the high dose point in particular seems to be a reasonable candidate explanation for some, but not all, of the convex nonlinearity seen in the data.

1
2
3

Table 5

Changes in Estimates of the Linear Slope Coefficient, ED10, and LED 10 for Dose Response Analyses Based on the Lowest 3 Exposure Groups

Risk Parameter	Analysis With Group Means of the Original Observations	Analysis With Group Means of the Lognormal Fit to Original Observations	Analysis With Revised Means After Subtracting GSD 1.95 Estimation Error Without "Scramble" Effect	Analysis With Revised Means After Subtracting GSD 3.2 Estimation Error Without "Scramble" Effect	Analysis With Revised Means After Subtracting GSD 1.95 Estimation Error With "Scramble" Effect	Analysis With Revised Means After Subtracting GSD 3.2 Estimation Error With "Scramble" Effect
est b	3.47E-04	3.34E-04	3.49E-04	3.80E-04	2.92E-04	2.75E-04
SE b	2.51E-04	2.43E-04	2.52E-04	2.71E-04	2.09E-04	1.93E-04
ucl b	7.60E-04	7.33E-04	7.62E-04	8.25E-04	6.36E-04	5.92E-04

4

5

6

7

Table 6

Changes in Estimates of the Linear Slope Coefficient, ED10, and LED 10 for Dose Response Analyses Based on All 4 Exposure Groups

Risk Parameter	Analysis With Group Means of the Original Observations	Analysis With Group Means of the Lognormal Fit to Original Observations	Analysis With Revised Means After Subtracting GSD 1.95 Estimation Error Without "Scramble" Effect	Analysis With Revised Means After Subtracting GSD 3.2 Estimation Error Without "Scramble" Effect	Analysis With Revised Means After Subtracting GSD 1.95 Estimation Error With "Scramble" Effect	Analysis With Revised Means After Subtracting GSD 3.2 Estimation Error With "Scramble" Effect
est b	4.54E-05	4.38E-05	5.77E-05	7.31E-05	5.52E-05	1.04E-04
SE b	3.28E-05	3.17E-05	4.06E-05	5.03E-05	3.81E-05	6.42E-05
ucl b	9.94E-05	9.60E-05	1.25E-04	1.56E-04	1.18E-04	2.10E-04

8

9

10

11

8-30-07 DRAFT

Science Advisory Board (SAB) Ethylene Oxide Review Panel Draft Advisory Report

-- Do Not Cite or Quote --

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

Appendix C

Framework Analysis of Genotoxicity and Risk Assessment

James Swenberg, PhD

1
2
3
4
5

Slide 1

Framework Analysis of Genotoxicity and Risk Assessment


James Swenberg
University of North Carolina

Slide 2


2005 EPA Guidelines for Carcinogen Risk Assessment

- *Linear extrapolation* should be used when there are Mode Of Action data to indicate that the dose-response curve is expected to have a linear component below the POD.
- Agents that are DNA-reactive and have direct mutagenic activity


Slide 3



Slide 4



Slide 5




Slide 6

Molecular Dosimetry of DNA Adducts

- DNA adducts are expected to be linear at low doses.
- An exception to this is when identical adducts are formed endogenously.
- Many forms of endogenous DNA adducts have been identified and measured. These include direct oxidative adducts, exocyclic adducts, AP sites and deamination products.


Slide 7

Linear DNA Adducts at Low Doses



Slide 8

MOA Key Events




Slide 9

Mutations Do Not Go Through Zero

- In contrast to most DNA adducts, mutations do not go through zero.
- Rather, they reach a spontaneous level that reflects the summation of endogenous DNA damage and repair that occurs in cells.
- The inflection point for a dose response curve where the number of mutations increases above the spontaneous level represents the point at which the exogenous DNA damage starts driving the biology of mutations.


Slide 10

Typical Mutation Dose Response




Slide 11

Historical Control Data for *HPRT* and TK Mutations *in vitro*




Slide 12



Slide 13


HPRT Mutation in AHH-1 cells with MMS



- Doses above **4µg/ml** MMS appear to be **cytotoxic**
- A possible threshold dose at **1µg/ml** MMS at the **HPRT** locus exists, with doses above 1µg/ml inducing significantly more mutants


Slide 14

MMS-induced TK^{-/-} Mutants




- The NOEL for mutation at the TK locus is located at 1µg/ml MMS - same as seen with HPRT locus.


Slide 15




Slide 16




Slide 17




Slide 18



Slide 19



Slide 20




Slide 21

DNA Repair Can Modulate Where the Inflection Point Occurs

- If DNA repair is impaired or absent, the inflection point for mutations occurs at lower doses.
- This results from increased numbers of DNA adducts relative to a cell of individuals with normal DNA repair.

Slide 22

Exposure-response for Mutagenesis in *Drosophila* Exposed By Inhalation To Propylene Oxide



⁶ Nivard et al, Mut. Res. 529: 95-107, 2003.

Slide 23

Ethylene Oxide


- Genotoxic in many systems including DNA adducts and *in vitro* and *in vivo* mutations.
- Known animal carcinogen.
- IARC Category 1 human carcinogen based on limited epidemiology data and human genetic toxicology.
- Formed endogenously in humans and animals from metabolism of ethylene.
- HEG is present in all human and animal cells.

Slide 24

Observed N7-HEG (pmol/umol Guanine)
following low-level EO exposure for 4 weeks

Tissue	ppm EO	Observed N7-HEG	
		Rats	Mice
Spleen	0	0.2	0.2
	3	2.5	0.5
	10	4.0	1.4
	33	8.8	5.6

Slide 25




Slide 26


EO *hprt* Mutations in Mice

Ethylene Concentration (ppm)	EO Concentration (or Estimated EO Concentration) (ppm)	Observed Mutant Frequency (x 10 ⁻⁶) Mean ± S.E. (n)
0.0	0.0	1.90 ± 0.16 (12)
40	(4.5 ± 2.0)	2.23 ± 0.14 (7)
1000	(9.0 ± 1.9)	1.27 ± 0.06 (7)
3000	(9.8 ± 3.0)	1.70 ± 0.18 (6)
	50	3.83 ± 0.44 (7)
	100	6.84 ± 0.86 (8)
	200	14.13 ± 1.13(9)

Slide 27



Slide 28



Slide 29

- ### Gaps in Knowledge
- Most mutation assays are done at high doses to establish that a compound is or is not genotoxic.
 - There is a real need to generate dose response data at low exposures to establish NOAELs for mutation in CA, MN and surrogate genes such as *hprt*.
 - These data will further establish the inflection points where the background number of mutations become increased.

Slide 30

Conclusions

- As our knowledge of carcinogenesis has expanded, concepts of “*one molecule* → *cancer*” have little to no scientific support.
- Mutations in genes controlling cell proliferation and cell death appear to play major roles in the induction of cancer.
- While these genes are difficult to monitor in noncancer tissues, surrogate mutations can be used to examine dose response in cells, animals and humans.

Slide 31

Conclusions (cont.)

- Such mutations do not have linear relationships with exposure. Rather, they reach a spontaneous incidence that is driven by endogenous biological processes.
- The inflection point for mutagenesis represents a much more strongly supported Point of Departure for setting acceptable exposures.
- This could be accomplished by using a Margin of Exposure approach to protect susceptible individuals.

1
2
3

Appendix D [Additional References]

4 Alexander FE, Patheal SL, Biondi A, Brandalise S, Cabrera ME, Chan LC, Chen Z, Cimino
5 G, Cordoba JC, Gu LJ, Hussein H, Ishii E, Kamel AM, Labra S, Magalhaes IQ, Mizutani S,
6 Petridou E, de Oliveira MP, Yuen P, Wiemels JL, Greaves MF. 2001. Transplacental
7 chemical exposure and risk of infant leukemia with MLL gene fusion. *Cancer Res.*
8 61(6):2542-2546.

9 Bender RP, Lindsey RH Jr, Burden DA, Osheroff N. 2004. N-acetyl-p-benzoquinone imine,
10 the toxic metabolite of acetaminophen, is a topoisomerase II poison. *Biochemistry.*
11 43(12):3731-3739.

12 Besaratinia A, Pfeifer, GP (2006). Investigating human cancer etiology by DNA lesion
13 footprinting and mutagenicity analysis. *Carcinogenesis* 27(8):1526-1537.

14 Bogen KT. 1998. Mechanistic model predicts a U-shaped relation of radon exposure to lung
15 cancer risk reflected in combined occupational and U.S. residential data. *Belle Newsletter*
16 7(2):9-14.

17 Bolt HM, Degen GH 2004. Human carcinogenic risk evaluation, Part II: Contributions of the
18 Eurotox Specialty Section for Carcinogenesis. *Toxicological Sciences* 81:3-6.

19 Branum ME, Reardon JT, Sancar A. 2001. Repair excision nuclease attacks undamaged
20 DNA. *Journal of Biological Chemistry* 276:25421-25426.

21 Brown SC, Schonbeck MF, McClure D, Baron AE, Navidi WC, Byers T, Rutenber AJ.
22 2004. Lung cancer and internal lung doses among plutonium workers at the Rocky Flats
23 Plant: a case-control study. *Am J Epidemiol.* 160(2):163-72.

24 Calabrese EJ, Baldwin LA, Holland CD.1999. Hormesis: A highly generalizable and
25 reproducible phenomenon with important implications for risk assessment. *Risk Anal.*
26 19(2):261-281.

27 Chan CL, Wu Z, Eastman A, Bresnick E. 1992. Irradiation-induced expression of O⁶-
28 methylguanine DNA methyltransferase in mammalian cells. *Cancer Research* 52:1804-1809.

29 Choudhury RC, Palo AK, Padhy A. 2004. Cytogenetic consequences of vinblastine treatment
30 in mouse bone marrow. *Chemotherapy.* 50(4):171-177.

31 Clarke CA, Purdie DM, Glaser SL. 2006. Population attributable risk of breast cancer in
32 white women associated with immediately modifiable risk factors. *BMC Cancer.* 6:170.

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

- 1 Corpet DE, Pierre F. 2005. How good are rodent models of carcinogenesis in predicting
2 efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in
3 rats, mice and men. *European Journal of Cancer* 41:1911-1922.
- 4 Crebelli R. 2000. Threshold-mediated mechanisms in mutagenesis: implications in the
5 classification and regulation of chemical mutagens. *Mutat. Res.* 464:129–135.
- 6 Crump K, Hoel D, Langley C, Peto R. 1976. Fundamental carcinogenic processes and their
7 implications to low-dose risk assessment. *Cancer Research* 36:2973-2979.
- 8 Csanady GA, Denk B, Putz C, Kreuzer PE, Kessler W, Baur C, Gargas ML, Filser JG. 2000.
9 A physiological toxicokinetic model for exogenous and endogenous ethylene and ethylene
10 oxide in rat, mouse, and human: Formation of 2-hydroxyethyl adducts with hemoglobin and
11 DNA. *Toxicol. Appl. Pharmacol.* 165:1-26.
- 12 Elhajouji A, Van Hummelen P, Kirsch-Volders M, 1995. Indications for a threshold of
13 chemically induced aneuploidy in vitro in human lymphocytes. *Environ. Mol. Mutagen.*
14 26:292-304.
- 15 Elhajouji A, Tibaldi F, Kirsch-Volders M. 1997. Indication for thresholds of chromosome
16 non-disjunction versus chromosome lagging induced by spindle inhibitors in vitro in human
17 lymphocytes. *Mutagenesis* 12:133-140.
- 18 Euhus DM, Cler L, Shivapurkar N, Milchgrub S, Peters GN, Leitch AM, Heda S, Gazdar
19 AF. 2002. Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk.
20 *J Natl Cancer Inst.* 94(11):858-860.
- 21 Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB, Greaves MF. 1977.
22 Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in
23 neonatal blood spots. *Proc. Natl. Acad. Sci. U.S.A.* 94:13950-13954.
- 24 Greaves, MF, 2004. Biologic models for leukaemia and lymphoma *IARC Sci Publ.* (157):
25 351-372.
- 26 Greaves MF 1999. Molecular genetics, natural history and the demise of childhood
27 leukaemia. *Eur. J. Cancer* 35:1941-1953.
- 28 Haseman JK 2003. An alternative perspective: A critical evaluation of the Waddell threshold
29 extrapolation model in chemical carcinogenesis. *Toxicologic Pathology* 31:468-470.
- 30 Hattis, D. 1990. Pharmacokinetic principles for dose rate extrapolation of carcinogenic risk
31 from genetically active agents, *Risk Analysis*, 10:303-316.
- 32 Henderson L, Albertini S, Aardema M. 2000. Thresholds in genotoxicity responses. *Mutat.*
33 *Res.* 464:123–128.

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

- 1 Hoel DG. 1985. Incorporation of pharmacokinetics in low-dose risk estimation. Chapter 10
2 in Toxicological Risk Assessment, Volume I. D. G. Clayson, D. Krewski, and I. Munro,
3 eds..
- 4 Hurtt ME, Thomas DA, Working PK, Monticello TM, Morgan KT. 1988. Degeneration and
5 regeneration of the olfactory epithelium following inhalation exposure to methyl bromide:
6 Pathology, cell kinetics, and olfactory function. *Toxicol. Appl. Pharmacol.* 94:311-328.
- 7 Kaden DA, Call KM, Leong PM, Komives EA, Thilly WG. 1987. Killing and mutation of
8 human lymphoblast cells by aflatoxin B1: Evidence for an inducible repair response.
9 *Cancer Research* 47:1993-2001.
- 10 Kirkland DJ, Muller L. 2000. Interpretation of the biological relevance of genotoxicity test
11 results: the importance of thresholds. *Mutat. Res.* 464:137-147.
- 12 Kirsch-Volders, M., Aardema, M., and Elhajouji, A. (2000). Concept of thresh-old in
13 mutagenesis and carcinogenesis. *Mutat. Res.* 464:3-11.
- 14 Lai DY. 2004. Rodent carcinogenicity of peroxisome proliferators and issues on human
15 relevance. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev.* 22(1):37-55.
- 16 Laib RJ, Klein KP, Bolt HM. 1985. The rat liver foci bioassay: I. Age-dependence of
17 induction by vinyl chloride of ATPase-deficient foci. *Carcinogenesis* 6(1):65-68.
- 18 Lightfoot TJ, Roman E. 2004. Causes of childhood leukaemia and lymphoma. *Toxicol Appl*
19 *Pharmacol.* 199(2):104-117.
- 20 Lovell DP 2000. Dose-response and threshold-mediated mechanisms in mutagenesis:
21 statistical models and study design. *Mutat. Res.* 464:87-95.
- 22 Lutz WK 1998. Dose-response relationships in chemical carcinogenesis: Superposition of
23 different mechanisms of action, resulting in linear-non-linear curves, practical thresholds, J-
24 shapes. *Mutation research* 405:117-124.
- 25 Lynch A, Harvey J, Aylott M., Nicholas E, Burman M, Siddiqui A, Walker S, Rees R. 2003.
26 Investigations into the concept of a threshold for topoisomerase inhibitor-induced
27 clastogenicity. *Mutagenesis* 18(4):345-353.
- 28 Madle S, von der Hude W, Bronschinski L, Janig GR. 2000. Threshold effects in genetic
29 toxicity: perspective of chemicals regulation in Germany. *Mutat. Res.* 464:117-121.
- 30 Metzger L, Iliakis G. 1991. Kinetics of DNA double-strand break repair throughout the cell
31 cycle as assayed by pulsed field gel electrophoresis in CHO cells. *Int. J. Radiat. Biol.*
32 59:1325-1339.
- 33 Moustacchi 2000. DNA damage and repair: consequences on dose-responses. *Mutat. Res.*
34 464:35-40.

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

- 1 Muller L, Kasper P. 2000. Human biological relevance and the use of threshold-arguments in
2 regulatory genotoxicity assessment; experience with pharmaceuticals. *Mutat. Res.* 464:19–
3 34.
- 4 Parry JM. 2000. Reflections on the implications of thresholds of mutagenic activity for the
5 labeling of chemicals by the European Union. *Mutat. Res.* 464:155-158.
- 6 Parry JM, Jenkins GJS, Haddad F, Bournier R, Parry EM. 2000. In vitro and in vivo
7 extrapolations of genotoxin exposures: consideration of factors which influence dose-
8 response thresholds. *Mutat. Res.* 464:53–63.
- 9 Radford IR. 1987 Effect of cell-cycle position and dose on the kinetics of DNA double-
10 strand breakage repair in X-irradiated Chinese hamster cells. *Int. J. Radiat. Biol* 52:555-563.
- 11 Ross JA. 1998. Maternal diet and infant leukemia: A role for DNA topoisomerase II
12 inhibitors? *Int. J. Cancer Suppl.* 11:26-28.
- 13 Schmerold I, Wiestler OD. 1986. Induction of rat liver O⁶-alkylguanine-DNA
14 alkyltransferase following whole body X-irradiation. *Cancer Research* 46:245-249.
- 15 Schulte-Hermann R, Grasl-Kraupp B, Bursch W. 2000. Dose-response and threshold effects
16 in cytotoxicity and apoptosis. *Mutat. Res.* 464:13–18.
- 17 Schulkin J. 2003. Rethinking Homeostasis—Allostatic Regulation in Physiology and
18 Pathophysiology. MIT Press, Cambridge, Massachusetts.
- 19 Slikker W Jr, Andersen ME, Bogdanffy MS, Bus JS, Cohen SD, Conolly RB, David RM,
20 Doerrer NG, Dorman DC, Gaylor DW, Hattis, D, Rogers JM, Setzer, RW, Swenberg, JA,
21 Wallace K. 2004. Dose-dependent transitions in mechanisms of toxicity.” *Toxicology and*
22 *Applied Pharmacology*, 201:203-225.
- 23 Spector LG, Xie Y, Robison LL, Heerema NA, Hilden JM, Lange B, Felix CA, Davies SM,
24 Slavin J, Potter JD, Blair CK, Reaman GH, Ross JA. 2005. Maternal diet and infant
25 leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's
26 oncology group. *Cancer Epidemiol Biomarkers Prev.* 14(3):651-655.
- 27 Speit G, Autrup H, Crebelli R, Henderson L, Kirsch-Volders M, Madle S, Parry JM, Sarrif
28 AM, Vrijhof H. 2000. Thresholds in genetic toxicology—concluding remarks. *Mutat. Res.*
29 464:149–153.
- 30 Stenerlow B, Hoglund E Carlsson J. Blomquist E. 2000. Rejoining of DNA fragments
31 produced by radiations of different linear energy transfer. *Int. J. Radiat. Biol.* 76: 549-557.
- 32 Stent GS. 1963. *Molecular Biology of Bacterial Viruses* W.H. Freeman and Company, San
33 Francisco, CA.

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

- 1 Swenberg JA, Kern WD, Mitchell RI, Gralla EJ, Pavkov KL. 1980. Induction of squamous
2 cell carcinomas of rat nasal cavity by inhalation exposure to formaldehyde vapor. Cancer
3 Res. 40:3398-3402.
- 4 Swenberg JA, Gross EA, Martin J, Popp JA. 1983. Mechanisms of formaldehyde toxicity.
5 Chapter 12 in Formaldehyde Toxicity. J. E. Gibson, ed. Hemisphere Publishing Corporation,
6 Washington DC, pp. 132-147.
- 7 Swenberg JA, Ham A, Koc H, Morinello E, Ranasinghe A, Tretyakova N, Upton PB, Wu
8 KY. 2000. DNA adducts: Effects of low exposure to ethylene oxide, vinyl chloride and
9 butadiene. Mutat. Res. 464:77-86.
- 10 U.S. Environmental Protection Agency. 1986. Guidelines for Carcinogen Risk Assessment
11 (1986). <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=54933> accessed 2/5/07.
- 12 U.S. Environmental Protection Agency. 2005. Guidelines for Carcinogen Risk Assessment
13 2005 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=116283>, accessed 2/5/07.
- 14 Waddell WJ. 2003. Thresholds in chemical carcinogenesis: What are the animal experiments
15 telling us? Toxicologic Pathology 31:260-262.
- 16 Waddell WJ. 2006. Critique of dose response in carcinogenesis. Human and Experimental
17 Toxicology 25:413-436.
- 18
19 World Health Organization Classification of Tumours: Pathology and Genetics of Tumours
20 of the Hematopoietic and Lymphoid Tissues, 2001, Jaffe et al. (ed.). IARC Press, Lyon,
21 France.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

1
2
3
4
5
6
7
8
14
15

ATTACHMENT 1 MEMO AND CHARGE QUESTIONS



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
OFFICE OF RESEARCH AND DEVELOPMENT
National Center for Environmental Assessment
Washington, DC 20460

October 27, 2006

NCEA Washington Office (8623D)

MEMORANDUM

SUBJECT: Request for SAB review of the Draft Ethylene Oxide (EtO) Carcinogenicity Assessment

David A Bussard

FROM: David A. Bussard, Director
National Center for Environmental Assessment-Washington (8623D)
Office of Research and Development

TO: Sue Shallal, Ph.D.
Designated Federal Officer
EPA Science Advisory Board Staff Office (1400F)

This is to request a review by the Science Advisory Board of the draft document entitled "Evaluation of the Carcinogenicity of Ethylene Oxide". This document is an assessment of the carcinogenicity of ethylene oxide (EtO). The assessment was prepared by the National Center for Environmental Assessment (NCEA), which is the health risk assessment program in the Office of Research and Development. The document has been made available for public comment on the Agency's NCEA web site at the following URL: <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=157664>. The assessment broadly supports activities authorized in the 1990 Clean Air Act and is of particular interest to EPA's Office of Air and Radiation. However, the assessment should also be applicable to the needs of all program Offices and Regions in evaluating the carcinogenicity of EtO.

EPA last published an assessment of the potential carcinogenicity of EtO in 1985. The current assessment reviews the more recent database on the carcinogenicity of EtO. The scientific literature search for this assessment is generally current through June 2004,

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 although a few later publications are included. This assessment focuses on lifetime cancer
2 risk from inhalation exposure.

3
4 EtO is a gas at room temperature. It is manufactured from ethylene and used
5 primarily as a chemical intermediate in the manufacture of ethylene glycol. It is also used as
6 a sterilizing agent for medical equipment and as a fumigating agent for spices. The largest
7 sources of human exposure are in occupations involving contact with the gas in plants
8 (facilities) and in hospitals that sterilize medical equipment. EtO can also be inhaled by
9 residents living near production or sterilizing/fumigating facilities. This document describes
10 the derivation of inhalation unit risk estimates for cancer mortality and incidence based on
11 human epidemiological data.

12
13 Attached is a draft of a charge to the Science Advisory Board that identifies the
14 questions and issues we want the Science Advisory Board to address in reviewing the
15 document.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

1
2
3
4
5 **CHARGE QUESTIONS FOR EPA'S SCIENCE ADVISORY BOARD (SAB) REVIEW**
6 **OF THE ETHYLENE OXIDE (EtO) CARCINOGENICITY ASSESSMENT**
7
8

9 EPA's Office of Research and Development (ORD) has requested that the Science
10 Advisory Board (SAB) review its document entitled "Evaluation of the Carcinogenicity of
11 Ethylene Oxide". This document is EPA's draft of the evaluation of the carcinogenicity of
12 ethylene oxide (EtO). The assessment was prepared by the National Center for
13 Environmental Assessment which is the health risk assessment program in the Office of
14 Research and Development. The assessment broadly supports activities authorized in the
15 1990 Clean Air Act and is of particular interest to EPA's Office of Air and Radiation.
16 However, this review also should be applicable to the needs of all program Offices and
17 Regions in evaluating the carcinogenicity of EtO.
18

19 EPA last published a health assessment of the potential carcinogenicity of EtO in
20 1985 (U.S. EPA, 1985). The current assessment reviews the more recent database on the
21 carcinogenicity of EtO. The scientific literature search for this assessment is generally
22 current through June 2004, although a few later publications are included. This assessment
23 focuses on lifetime cancer risk from inhalation exposure.
24

25 EtO is a gas at room temperature. It is manufactured from ethylene and used
26 primarily as a chemical intermediate in the manufacture of ethylene glycol. It is also used as
27 a sterilizing agent for medical equipment and as a fumigating agent for spices. The largest
28 sources of human exposure are in occupations involving contact with the gas in plants
29 (facilities) and in hospitals that sterilize medical equipment. EtO can also be inhaled by
30 residents living near production or sterilizing/fumigating facilities.
31

32 The DNA-damaging properties of EtO have been studied since the 1940s. EtO is
33 known to be mutagenic in a large number of living organisms, ranging from bacteriophage to
34 mammals, and it also induces chromosome damage. It is carcinogenic in mice and rats,
35 inducing tumors of the lymphohematopoietic system, brain, lung, connective tissue, uterus,
36 and mammary gland. In humans employed in EtO-manufacturing facilities and in sterilizing
37 facilities, the greatest evidence of a cancer risk from exposure is for cancer of the
38 lymphohematopoietic system. Increases in the risk of lymphohematopoietic cancer have
39 been seen in several studies, manifested as an increase either in leukemia and/or in cancer of
40 the lymphoid tissue. In one large epidemiologic study of sterilizer workers that had a well-
41 defined exposure assessment for individuals, positive exposure-response trends for
42 lymphohematopoietic cancer mortality in males and for breast cancer mortality in females
43 were reported (Steenland et al., 2004). The positive exposure-response trend for female
44 breast cancer was confirmed in an incidence study based on the same worker cohort
45 (Steenland et al., 2003).

1
2 In accordance with EPA's 2005 *Guidelines for Carcinogen Risk Assessment* (U.S.
3 EPA, 2005a), EtO was characterized as carcinogenic to humans based on the total weight of
4 evidence.

5
6 This evidence, as assessed by EPA, included:

- 7
8 a) strong, though less than completely conclusive, evidence of carcinogenicity from
9 human studies
10 b) sufficient evidence of carcinogenicity in laboratory animals
11 c) EtO is a direct-acting alkylating agent with clear evidence of
12 mutagenicity/genotoxicity, and there is sufficient evidence that DNA adduct formation
13 and the resulting mutagenic/genotoxic effects are key events in the mode of action of EtO
14 carcinogenicity
15 d) evidence of chromosome damage in humans exposed to EtO, supporting the inference
16 that the same mode of action for EtO carcinogenicity is operative in humans
17

18 This document describes the derivation of inhalation unit risk estimates for cancer
19 mortality and incidence based on the human data. An EC_{01} of $44 \mu\text{g}/\text{m}^3$ (0.024 ppm) was
20 calculated using a life-table analysis and linear modeling of the categorical Cox regression
21 analysis results for excess lymphohematopoietic cancer mortality in males reported in a high-
22 quality occupational epidemiologic study (Steenland et al., 2004). Linear low-dose
23 extrapolation from the LEC_{01} yielded a lifetime extra cancer mortality unit risk estimate of
24 5.0×10^{-4} per $\mu\text{g}/\text{m}^3$ (0.92 per ppm) of continuous EtO exposure. Applying the same linear
25 regression coefficient and life-table analysis to background male lymphohematopoietic
26 cancer *incidence* rates yielded an EC_{01} of $24 \mu\text{g}/\text{m}^3$ (0.013 ppm) and a preferred lifetime
27 extra cancer unit risk estimate of 9.0×10^{-4} per $\mu\text{g}/\text{m}^3$ (1.6 per ppm). The preferred estimate
28 is greater than the estimate of 5.0×10^{-4} per $\mu\text{g}/\text{m}^3$ (0.91 per ppm; $EC_{01} = 44 \mu\text{g}/\text{m}^3$)
29 calculated, using the same approach, from the results of a breast cancer incidence study of
30 the same worker cohort (Steenland et al., 2003), and is recommended as the potency estimate
31 for Agency use.
32

33 Because the weight of evidence supports a mutagenic mode of action for EtO
34 carcinogenicity, and in the absence of chemical-specific data on early-life susceptibility, this
35 assessment finds that increased early-life susceptibility should be assumed and the age-
36 dependent adjustment factors (ADAFs) should be applied, in accordance with EPA's
37 *Supplemental Guidance for Assessing Susceptibility From Early-Life Exposure to*
38 *Carcinogens*, hereinafter referred to as "EPA's Supplemental Guidance" (U.S. EPA, 2005b).
39 Applying the ADAFs to the unit risk estimate of 9.0×10^{-4} per $\mu\text{g}/\text{m}^3$ yields an adjusted full
40 lifetime unit risk estimate of 1.5×10^{-3} per $\mu\text{g}/\text{m}^3$, and the commensurate lifetime chronic
41 exposure level of EtO corresponding to an increased cancer risk of 10^{-6} is $0.0007 \mu\text{g}/\text{m}^3$.
42 [Note that for less-than-lifetime exposure scenarios (or for exposures that vary with age), the
43 unadjusted (adult-based) potency estimate of 9.0×10^{-4} per $\mu\text{g}/\text{m}^3$ should be used, in
44 conjunction with the ADAFs as appropriate, in accordance with EPA's Supplemental
45 Guidance.]

1
2 Unit risk estimates were also derived from the three chronic rodent bioassays for EtO
3 reported in the literature. These estimates, ranging from 2.2×10^{-5} per $\mu\text{g}/\text{m}^3$ to 4.6×10^{-5}
4 per $\mu\text{g}/\text{m}^3$, are about an order of magnitude lower than the estimates based on human data
5 [unadjusted for early-life susceptibility]. The Agency takes the position that human data, if
6 adequate data are available, provide a more appropriate basis than rodent data for estimating
7 population risks (U.S. EPA, 2005a), primarily because uncertainties in extrapolating
8 quantitative risks from rodents to humans are avoided. Although there is a fairly sizable
9 difference between the rodent- and human-based estimates, the assessment infers that the
10 similarity between the unit risk estimates based on the male lymphohematopoietic cancer and
11 the female breast cancer results increases confidence in the use of the unit risk estimate based
12 on the male lymphohematopoietic cancer results.

13
14 The unit risk estimates were developed for environmental exposure levels and are not
15 necessarily applicable to higher-level occupational exposures, which appear to be subject to a
16 different exposure-response relationship. However, occupational exposure levels are of
17 concern to EPA when EtO is used as a pesticide (e.g., fumigant for spices). Therefore, this
18 document also presents extra risk estimates for cancer for a number of occupational exposure
19 scenarios.

20
21 The SAB Ethylene Oxide Review Panel is being asked to comment on the scientific
22 soundness of this carcinogenicity assessment. The specific charge questions to the Panel are
23 as follows:

24
25 **Issue 1: Carcinogenic Hazard (Section 3 and Appendix A of the Draft)**

26
27 1. Do the available data and discussion in the draft document support the hazard conclusion
28 that EtO is carcinogenic to humans based on the weight-of-evidence descriptors in EPA's
29 2005 *Guidelines for Carcinogen Risk Assessment*? In your response, please include
30 consideration of the following:

31
32 1.a EPA concluded that the epidemiological evidence on EtO carcinogenicity was strong, but
33 less than completely conclusive. Does the draft document provide sufficient description of
34 the studies, balanced treatment of positive and negative results, and a rigorous and
35 transparent analysis of the data used to assess the carcinogenic hazard of ethylene oxide
36 (EtO) to humans? Please comment on the EPA's characterization of the body of
37 epidemiological data reviewed. Considerations include: a) the consistency of the findings,
38 including the significance of differences in results using different exposure metrics, b) the
39 utility of the internal (based on exposure category) versus external (e.g., SMR and SIR)
40 comparisons of cancer rates, c) the magnitude of the risks, and d) the strength of the
41 epidemiological evidence.

42
43 1.b. Are there additional key published studies or publicly available scientific reports that
44 are missing from the draft document and that might be useful for the discussion of the
45 carcinogenic hazard of EtO?

1
2 1.c. Do the available data and discussion in the draft document support the mode of action
3 conclusions?
4

5 1.d. Does the hazard characterization discussion for EtO provide a scientifically-balanced
6 and sound description that synthesizes the human, laboratory animal, and supporting (e.g., *in*
7 *vitro*) evidence for human carcinogenic hazard?
8
9

10 **Issue 2: Risk Estimation (Section 4 and Appendices C and D)**
11

12 2. Do the available data and discussion in the draft document support the approaches taken
13 by EPA in its derivation of cancer risk estimates for EtO? In your response, please include
14 consideration of the following:
15

16 2.a. EPA concluded that the epidemiological evidence alone was strong but less than
17 completely conclusive (although EPA characterized the total evidence - from human,
18 laboratory animal, and *in vitro* studies - as supporting a conclusion that EtO as "carcinogenic
19 to humans"). Is the use of epidemiological data, in particular the Steenland et al. (2003,
20 2004) data set, the most appropriate for estimating the magnitude of the carcinogenic risk to
21 humans from environmental EtO exposures? Are the scientific justifications for using this
22 data set transparently described? Is the basis for selecting the Steenland et al. data over other
23 available data (e.g., the Union Carbide data) for quantifying risk adequately described?
24

25 2.b. Assuming that Steenland et al. (2003, 2004) is the most appropriate data set, is the use
26 of a linear regression model fit to Steenland et al.'s categorical results for all
27 lymphohematopoietic cancer in males in only the lower exposure groups scientifically and
28 statistically appropriate for estimating potential human risk at the lower end of the
29 observable range? Is the use of the grouping of all lymphohematopoietic cancer for the
30 purpose of estimating risk appropriate? Are there other appropriate analytical approaches
31 that should be considered for estimating potential risk in the lower end of the observable
32 range? Is EPA's choice of a preferred model adequately supported and justified? In
33 particular, has EPA adequately explained its reasons for not using a quadratic model
34 approach such as that of Kirman et al. (2004) based? What recommendations would you
35 make regarding low-dose extrapolation below the observed range?
36

37 2.c. Is the incorporation of age-dependent adjustment factors in the lifetime cancer unit risk
38 estimate, in accordance with EPA's Supplemental Guidance (U.S. 2005b), appropriate and
39 transparently described?
40

41 2.d. Is the use of different models for estimation of potential carcinogenic risk to humans
42 from the higher exposure levels more typical of occupational exposures (versus the lower
43 exposure levels typical of environmental exposures) appropriate and transparently described
44 in Section 4.5?
45

This Draft is made available for review and approval by the chartered Science Advisory Board.

This Draft does not represent EPA policy.

1 2.e. Are the methodologies used to estimate the carcinogenic risk based on rodent data
2 appropriate and transparently described? Is the use of “ppm equivalence” adequate for
3 interspecies scaling of EtO exposures from the rodent data to humans?
4

5 **Issue 3: Uncertainty (Sections 3 and 4)**
6

7 1. EPA’s *Risk Characterization Handbook* requires that assessments address in a transparent
8 manner a number of important factors. Please comment on how well this assessment clearly
9 describes, characterizes and communicates the following:
10

- 11 a. The assessment approach employed;
- 12 b. The use of assumptions and their impact on the assessment;
- 13 c. The use of extrapolations and their impact on the assessment;
- 14 d. Plausible alternatives and the choices made among those alternatives;
- 15 e. The impact of one choice versus another on the assessment;
- 16 f. Significant data gaps and their implications for the assessment;
- 17 g. The scientific conclusions identified separately from default assumptions and
18 policy calls;
- 19 h. The major risk conclusions and the assessor’s confidence and uncertainties in
20 them, and;
- 21 i. The relative strength of each risk assessment component and its impact on the
22 overall assessment.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41